Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof

ABSTRACT

The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the enzyme peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the enzyme peptides, and methods of identifying modulators of the enzyme peptides.

This application is a Division of U.S. application Ser. No. 09/820,924 filed Mar. 30, 2001, now U.S. Pat. No. 6,555,351 issued Apr. 29, 2003.

FIELD OF THE INVENTION

The present invention is in the field of enzyme proteins that are related to the trans-prenyltransferase subfamily, recombinant DNA molecules, and protein production. The present invention specifically provides novel peptides and proteins and nucleic acid molecules encoding such peptide and protein molecules, all of which are useful in the development of human therapeutics and diagnostic compositions and methods.

BACKGROUND OF THE INVENTION

Many human enzymes serve as targets for the action of pharmaceutically active compounds. Several classes of human enzymes that serve as such targets include helicase, steroid esterase and sulfatase, convertase, synthase, dehydrogenase, monoxygenase, transferase, kinase, glutanase, decarboxylase, isomerase and reductase. It is therefore important in developing new pharmaceutical compounds to identify target enzyme proteins that can be put into high-throughput screening formats. The present invention advances the state of the art by providing novel human drug target enzymes related to the trans-prenyltransferase subfamily.

The present invention has substantial similarity to trans-prenyltransferase (polyprenyl pyrophosphate synthetase). Trans-prenyltransferase synthesizes the side-chain moiety of coenzyme Q, taking place in microsomes of Golgi system. Trans-prenyltransferase, a ubiquitous protein, is a member of the coenzyme Q biosynthesis pathway, and a very important enzyme involved in biosynthesis of polyprenyls and coenzyme Q. CoQ synthesis is also dependent on trans-prenyltransferase activity on the level of intracellular substrate concentration. In addition, CoQ level may be regulated in blood as well as in various tissues. Thus, the enzyme of the present invention may be a potential drug target for anti-cancer treatment. For a review related to trans-prenyltransferase, see Appelkvist et al., Mol Aspects Med 1994;15 Suppl:s37-46; Rotig et al., Lancet Jul. 29, 2000;356(9227):391-5.

Enzyme proteins, particularly members of the trans-prenyltransferase subfamily, are a major target for drug action and development. Accordingly, it is valuable to the field of pharmaceutical development to identify and characterize previously unknown members of this subfamily of enzyme proteins. The present invention advances the state of the art by providing previously unidentified human enzyme proteins, and the polynucleotides encoding them, that have homology to members of the trans-prenyltransferase subfamily. These novel compositions are useful in the diagnosis, prevention and treatment of biological processes associated with human diseases.

SUMMARY OF THE INVENTION

The present invention is based in part on the identification of amino acid sequences of human enzyme peptides and proteins that are related to the trans-prenyltransferase subfamily, as well as allelic variants and other mammalian orthologs thereof. These unique peptide sequences, and nucleic acid sequences that encode these peptides, can be used as models for the development of human therapeutic targets, aid in the identification of therapeutic proteins, and serve as targets for the development of human therapeutic agents that modulate enzyme activity in cells and tissues that express the enzyme. Experimental data as provided in FIG. 1 indicates expression in humans in the T cells from T cell leukemia, B cells from Burkitt lymphoma, neuroblastoma cells, duodenal adenocarcinoma cell line, adenocarcinoma cell line, stomach, breast, whole liver.

DESCRIPTION OF THE FIGURE SHEETS

FIGS. 1A-1B provide the nucleotide sequence of a cDNA molecule sequence that encodes the enzyme protein of the present invention. (SEQ ID NO: 1) In addition, structure and functional information is provided, such as ATG start, stop and tissue distribution, where available, that allows one to readily determine specific uses of inventions based on this molecular sequence. Experimental data as provided in FIG. 1 indicates expression in humans in the T cells from T cell leukemia, B cells from Burkitt lymphoma, neuroblastoma cells, duodenal adenocarcinoma cell line, adenocarcinoma cell line, stomach, breast, whole liver.

FIGS. 2A-2B provide the predicted amino acid sequence of the enzyme of the present invention. (SEQ ID NO:2) In addition structure and functional information such as protein family, function, and modification sites is provided where available, allowing one to readily determine specific uses of inventions based on this molecular sequence.

FIGS. 3A-3U provide genomic sequences that span the gene encoding the enzyme protein of the present invention. (SEQ ID NO:3) In addition structure and functional information, such as intron/exon structure, promoter location, etc., is provided where available, allowing one to readily determine specific uses of inventions based on this molecular sequence. 57 SNPs, including 8 indels, have been identified in the gene encoding the enzyme protein provided by the present invention and are given in FIG. 3.

DETAILED DESCRIPTION OF THE INVENTION

General Description

The present invention is based on the sequencing of the human genome. During the sequencing and assembly of the human genome, analysis of the sequence information revealed previously unidentified fragments of the human genome that encode peptides that share structural and/or sequence homology to protein/peptide/domains identified and characterized within the art as being a enzyme protein or part of a enzyme protein and are related to the trans-prenyltransferase subfamily. Utilizing these sequences, additional genomic sequences were assembled and transcript and/or cDNA sequences were isolated and characterized. Based on this analysis, the present invention provides amino acid sequences of human enzyme peptides and proteins that are related to the trans-prenyltransferase subfamily, nucleic acid sequences in the form of transcript sequences, cDNA sequences and/or genomic sequences that encode these enzyme peptides and proteins, nucleic acid variation (allelic information), tissue distribution of expression, and information about the closest art known protein/peptide/domain that has structural or sequence homology to the enzyme of the present invention.

In addition to being previously unknown, the peptides that are provided in the present invention are selected based on their ability to be used for the development of commercially important products and services. Specifically, the present peptides are selected based on homology and/or structural relatedness to known enzyme proteins of the trans-prenyltransferase subfamily and the expression pattern observed. Experimental data as provided in FIG. 1 indicates expression in humans in the T cells from T cell leukemia, B cells from Burkitt lymphoma, neuroblastoma cells, duodenal adenocarcinoma cell line, adenocarcinoma cell line, stomach, breast, whole liver. The art has clearly established the commercial importance of members of this family of proteins and proteins that have expression patterns similar to that of the present gene. Some of the more specific features of the peptides of the present invention, and the uses thereof, are described herein, particularly in the Background of the Invention and in the annotation provided in the Figures, and/or are known within the art for each of the known trans-prenyltransferase family or subfamily of enzyme proteins.

Specific Embodiments

Peptide Molecules

The present invention provides nucleic acid sequences that encode protein molecules that have been identified as being members of the enzyme family of proteins and are related to the trans-prenyltransferase subfamily (protein sequences are provided in FIG. 2, transcript/cDNA sequences are provided in FIG. 1 and genomic sequences are provided in FIG. 3). The peptide sequences provided in FIG. 2, as well as the obvious variants described herein, particularly allelic variants as identified herein and using the information in FIG. 3, will be referred herein as the enzyme peptides of the present invention, enzyme peptides, or peptides/proteins of the present invention.

The present invention provides isolated peptide and protein molecules that consist of, consist essentially of, or comprise the amino acid sequences of the enzyme peptides disclosed in the FIG. 2, (encoded by the nucleic acid molecule shown in FIG. 1, transcript/cDNA or FIG. 3, genomic sequence), as well as all obvious variants of these peptides that are within the art to make and use. Some of these variants are described in detail below.

As used herein, a peptide is said to be “isolated” or “purified” when it is substantially free of cellular material or free of chemical precursors or other chemicals. The peptides of the present invention can be purified to homogeneity or other degrees of purity. The level of purification will be based on the intended use. The critical feature is that the preparation allows for the desired function of the peptide, even if in the presence of considerable amounts of other components (the features of an isolated nucleic acid molecule is discussed below).

In some uses, “substantially free of cellular material” includes preparations of the peptide having less than about 30% (by dry weight) other proteins (i.e., contaminating protein), less than about 20% other proteins, less than about 10% other proteins, or less than about 5% other proteins. When the peptide is recombinantly produced, it can also be substantially free of culture medium, i.e., culture medium represents less than about 20% of the volume of the protein preparation.

The language “substantially free of chemical precursors or other chemicals” includes preparations of the peptide in which it is separated from chemical precursors or other chemicals that are involved in its synthesis. In one embodiment, the language “substantially free of chemical precursors or other chemicals” includes preparations of the enzyme peptide having less than about 30% (by dry weight) chemical precursors or other chemicals, less than about 20% chemical precursors or other chemicals, less than about 10% chemical precursors or other chemicals, or less than about 5% chemical precursors or other chemicals.

The isolated enzyme peptide can be purified from cells that naturally express it, purified from cells that have been altered to express it (recombinant), or synthesized using known protein synthesis methods. Experimental data as provided in FIG. 1 indicates expression in humans in the T cells from T cell leukemia, B cells from Burkitt lymphoma, neuroblastoma cells, duodenal adenocarcinoma cell line, adenocarcinoma cell line, stomach, breast, whole liver. For example, a nucleic acid molecule encoding the enzyme peptide is cloned into an expression vector, the expression vector introduced into a host cell and the protein expressed in the host cell. The protein can then be isolated from the cells by an appropriate purification scheme using standard protein purification techniques. Many of these techniques are described in detail below.

Accordingly, the present invention provides proteins that consist of the amino acid sequences provided in FIG. 2 (SEQ ID NO:2), for example, proteins encoded by the transcript/cDNA nucleic acid sequences shown in FIG. 1 (SEQ ID NO:1) and the genomic sequences provided in FIG. 3 (SEQ ID NO:3). The amino acid sequence of such a protein is provided in FIG. 2. A protein consists of an amino acid sequence when the amino acid sequence is the final amino acid sequence of the protein.

The present invention further provides proteins that consist essentially of the amino acid sequences provided in FIG. 2 (SEQ ID NO:2), for example, proteins encoded by the transcript/cDNA nucleic acid sequences shown in FIG. 1 (SEQ ID NO:1) and the genomic sequences provided in FIG. 3 (SEQ ID NO:3). A protein consists essentially of an amino acid sequence when such an amino acid sequence is present with only a few additional amino acid residues, for example from about 1 to about 100 or so additional residues, typically from 1 to about 20 additional residues in the final protein.

The present invention further provides proteins that comprise the amino acid sequences provided in FIG. 2 (SEQ ID NO:2), for example, proteins encoded by the transcript/cDNA nucleic acid sequences shown in FIG. 1 (SEQ ID NO:1) and the genomic sequences provided in FIG. 3 (SEQ ID NO:3). A protein comprises an amino acid sequence when the amino acid sequence is at least part of the final amino acid sequence of the protein. In such a fashion, the protein can be only the peptide or have additional amino acid molecules, such as amino acid residues (contiguous encoded sequence) that are naturally associated with it or heterologous amino acid residues/peptide sequences. Such a protein can have a few additional amino acid residues or can comprise several hundred or more additional amino acids. The preferred classes of proteins that are comprised of the enzyme peptides of the present invention are the naturally occurring mature proteins. A brief description of how various types of these proteins can be made/isolated is provided below.

The enzyme peptides of the present invention can be attached to heterologous sequences to form chimeric or fusion proteins. Such chimeric and fusion proteins comprise a enzyme peptide operatively linked to a heterologous protein having an amino acid sequence not substantially homologous to the enzyme peptide. “Operatively linked” indicates that the enzyme peptide and the heterologous protein are fused in-frame. The heterologous protein can be fused to the N-terminus or C-terminus of the enzyme peptide.

In some uses, the fusion protein does not affect the activity of the enzyme peptide per se. For example, the fusion protein can include, but is not limited to, enzymatic fusion proteins, for example beta-galactosidase fusions, yeast two-hybrid GAL fusions, poly-His fusions, MYC-tagged, HI-tagged and Ig fusions. Such fusion proteins, particularly poly-His fusions, can facilitate the purification of recombinant enzyme peptide. In certain host cells (e.g., mammalian host cells), expression and/or secretion of a protein can be increased by using a heterologous signal sequence.

A chimeric or fusion protein can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different protein sequences are ligated together in-frame in accordance with conventional techniques. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and re-amplified to generate a chimeric gene sequence (see Ausubel et al., Current Protocols in Molecular Biology, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST protein). A enzyme peptide-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the enzyme peptide.

As mentioned above, the present invention also provides and enables obvious variants of the amino acid sequence of the proteins of the present invention, such as naturally occurring mature forms of the peptide, allelic/sequence variants of the peptides, non-naturally occurring recombinantly derived variants of the peptides, and orthologs and paralogs of the peptides. Such variants can readily be generated using art-known techniques in the fields of recombinant nucleic acid technology and protein biochemistry. It is understood, however, that variants exclude any amino acid sequences disclosed prior to the invention.

Such variants can readily be identified/made using molecular techniques and the sequence information disclosed herein. Further, such variants can readily be distinguished from other peptides based on sequence and/or structural homology to the enzyme peptides of the present invention. The degree of homology/identity present will be based primarily on whether the peptide is a functional variant or non-functional variant, the amount of divergence present in the paralog family and the evolutionary distance between the orthologs.

To determine the percent identity of two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% or more of the length of a reference sequence is aligned for comparison purposes. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid “identity” is equivalent to amino acid or nucleic acid “homology”). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

The comparison of sequences and determination of percent identity and similarity between two sequences can be accomplished using a mathematical algorithm. (Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part 1, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch (J. Mol. Biol. (48):444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at http://www.gcg.com), using either a Blossom 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (Devereux, J., et al., Nucleic Acids Res. 12(1):387 (1984)) (available at http://www.gcg.com), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. In another embodiment, the percent identity between two amino acid or nucleotide sequences is determined using the algorithm of E. Myers and W. Miller (CABIOS, 4:11-17 (1989)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of. 4.

The nucleic acid and protein sequences of the present invention can further be used as a “query sequence” to perform a search against sequence databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (J. Mol. Biol. 215:403-10 (1990)). BLAST nucleotide searches can be performed with the NBLAST program, score=100, wordlength=12 to obtain nucleotide sequences homologous to the nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score=50, wordlength=3 to obtain amino acid sequences homologous to the proteins of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al. (Nucleic Acids Res. 25(17):3389-3402 (1997)). When utilizing BLAST and gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used.

Full-length pre-processed forms, as well as mature processed forms, of proteins that comprise one of the peptides of the present invention can readily be identified as having complete sequence identity to one of the enzyme peptides of the present invention as well as being encoded by the same genetic locus as the enzyme peptide provided herein. As indicated by the data presented in FIG. 3, the map position was determined to be on chromosome 10 by ePCR.

Allelic variants of a enzyme peptide can readily be identified as being a human protein having a high degree (significant) of sequence homology/identity to at least a portion of the enzyme peptide as well as being encoded by the same genetic locus as the enzyme peptide provided herein. Genetic locus can readily be determined based on the genomic information provided in FIG. 3, such as the genomic sequence mapped to the reference human. As indicated by the data presented in FIG. 3, the map position was determined to be on chromosome 10 by ePCR. As used herein, two proteins (or a region of the proteins) have significant homology when the amino acid sequences are typically at least about 70-80%, 80-90%, and more typically at least about 90-95% or more homologous. A significantly homologous amino acid sequence, according to the present invention, will be encoded by a nucleic acid sequence that will hybridize to a enzyme peptide encoding nucleic acid molecule under stringent conditions as more filly described below.

FIG. 3 provides information on SNPs that have been found in the gene encoding the enzyme protein of the present invention. SNPs were identified at 57 different nucleotide positions in introns and regions 5′ and 3′ of the ORF. Such SNPs in introns and outside the ORF may affect control/regulatory elements.

Paralogs of a enzyme peptide can readily be identified as having some degree of significant sequence homology/identity to at least a portion of the enzyme peptide, as being encoded by a gene from humans, and as having similar activity or function. Two proteins will typically be considered paralogs when the amino acid sequences are typically at least about 60% or greater, and more typically at least about 70% or greater homology through a given region or domain. Such paralogs will be encoded by a nucleic acid sequence that will hybridize to a enzyme peptide encoding nucleic acid molecule under moderate to stringent conditions as more fully described below.

Orthologs of a enzyme peptide can readily be identified as having some degree of significant sequence homology/identity to at least a portion of the enzyme peptide as well as being encoded by a gene from another organism. Preferred orthologs will be isolated from mammals, preferably primates, for the development of human therapeutic targets and agents. Such orthologs will be encoded by a nucleic acid sequence that will hybridize to a enzyme peptide encoding nucleic acid molecule under moderate to stringent conditions, as more fully described below, depending on the degree of relatedness of the two organisms yielding the proteins.

Non-naturally occurring variants of the enzyme peptides of the present invention can readily be generated using recombinant techniques. Such variants include, but are not limited to deletions, additions and substitutions in the amino acid sequence of the enzyme peptide. For example, one class of substitutions are conserved amino acid substitution. Such substitutions are those that substitute a given amino acid in a enzyme peptide by another amino acid of like characteristics. Typically seen as conservative substitutions are the replacements, one for another, among the aliphatic amino acids Ala, Val, Leu, and Ile; interchange of the hydroxyl residues Ser and Thr; exchange of the acidic residues Asp and Glu; substitution between the amide residues Asn and Gln; exchange of the basic residues Lys and Arg; and replacements among the aromatic residues Phe and Tyr. Guidance concerning which amino acid changes are likely to be phenotypically silent are found in Bowie et al., Science 247:1306-1310 (1990).

Variant enzyme peptides can be fully functional or can lack function in one or more activities, e.g. ability to bind substrate, ability to phosphorylate substrate, ability to mediate signaling, etc. Fully functional variants typically contain only conservative variation or variation in non-critical residues or in non-critical regions. FIG. 2 provides the result of protein analysis and can be used to identify critical domains/regions. Functional variants can also contain substitution of similar amino acids that result in no change or an insignificant change in function. Alternatively, such substitutions may positively or negatively affect function to some degree.

Non-functional variants typically contain one or more non-conservative amino acid substitutions, deletions, insertions, inversions, or truncation or a substitution, insertion, inversion, or deletion in a critical residue or critical region.

Amino acids that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham et al., Science 244:1081-1085 (1989)), particularly using the results provided in FIG. 2. The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity such as enzyme activity or in assays such as an in vitro proliferative activity. Sites that are critical for binding partner/substrate binding can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith et al., J. Mol. Biol. 224:899-904 (1992); de Vos et al. Science 255:306-312 (1992)).

The present invention further provides fragments of the enzyme peptides, in addition to proteins and peptides that comprise and consist of such fragments, particularly those comprising the residues identified in FIG. 2. The fragments to which the invention pertains, however, are not to be construed as encompassing fragments that may be disclosed publicly prior to the present invention.

As used herein, a fragment comprises at least 8, 10, 12, 14, 16, or more contiguous amino acid residues from a enzyme peptide. Such fragments can be chosen based on the ability to retain one or more of the biological activities of the enzyme peptide or could be chosen for the ability to perform a function, e.g. bind a substrate or act as an immunogen. Particularly important fragments are biologically active fragments, peptides that are, for example, about 8 or more amino acids in length. Such fragments will typically comprise a domain or motif of the enzyme peptide, e.g., active site, a transmembrane domain or a substrate-binding domain. Further, possible fragments include, but are not limited to, domain or motif containing fragments, soluble peptide fragments, and fragments containing immunogenic structures. Predicted domains and functional sites are readily identifiable by computer programs well known and readily available to those of skill in the art (e.g., PROSITE analysis). The results of one such analysis are provided in FIG. 2.

Polypeptides often contain amino acids other than the 20 amino acids commonly referred to as the 20 naturally occurring amino acids. Further, many amino acids, including the terminal amino acids, may be modified by natural processes, such as processing and other post-translational modifications, or by chemical modification techniques well known in the art. Common modifications that occur naturally in enzyme peptides are described in basic texts, detailed monographs, and the research literature, and they are well known to those of skill in the art (some of these features are identified in FIG. 2).

Known modifications include, but are not limited to, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent crosslinks, formation of cystine, formation of pyroglutamate, formylation, gamma carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.

Such modifications are well known to those of skill in the art and have been described in great detail in the scientific literature. Several particularly common modifications, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation, for instance, are described in most basic texts, such as Proteins—Structure and Molecular Properties, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993). Many detailed reviews are available on this subject, such as by Wold, F., Posttranslational Covalent Modification of Proteins, B. C. Johnson, Ed., Academic Press, New York 1-12 (1983); Seifter et al. (Meth. Enzymol. 182: 626-646 (1990)) and Rattan et al. (Ann. N.Y. Acad. Sci. 663:48-62 (1992)).

Accordingly, the enzyme peptides of the present invention also encompass derivatives or analogs in which a substituted amino acid residue is not one encoded by the genetic code, in which a substituent group is included, in which the mature enzyme peptide is fused with another compound, such as a compound to increase the half-life of the enzyme peptide (for example, polyethylene glycol), or in which the additional amino acids are fused to the mature enzyme peptide, such as a leader or secretory sequence or a sequence for purification of the mature enzyme peptide or a pro-protein sequence.

Protein/Peptide Uses

The proteins of the present invention can be used in substantial and specific assays related to the functional information provided in the Figures; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its binding partner or ligand) in biological fluids; and as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state). Where the protein binds or potentially binds to another protein or ligand (such as, for example, in a enzyme-effector protein interaction or enzyme-ligand interaction), the protein can be used to identify the binding partner/ligand so as to develop a system to identify inhibitors of the binding interaction. Any or all of these uses are capable of being developed into reagent grade or kit format for commercialization as commercial products.

Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include “Molecular Cloning: A Laboratory Manual”, 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E. F. Fritsch and T. Maniatis eds., 1989, and “Methods in Enzymology: Guide to Molecular Cloning Techniques”, Academic Press, Berger, S. L. and A. R. Kimmel eds., 1987.

The potential uses of the peptides of the present invention are based primarily on the source of the protein as well as the class/action of the protein. For example, enzymes isolated from humans and their human/mammalian orthologs serve as targets for identifying agents for use in mammalian therapeutic applications, e.g. a human drug, particularly in modulating a biological or pathological response in a cell or tissue that expresses the enzyme. Experimental data as provided in FIG. 1 indicates that the enzymes of the present invention are expressed in humans in the T cells from T cell leukemia, B cells from Burkitt lymphoma, neuroblastoma cells, duodenal adenocarcinoma cell line, adenocarcinoma cell line, stomach and breast detected by a virtual northern blot. In addition, PCR-based tissue screening panels indicate expression in whole liver. A large percentage of pharmaceutical agents are being developed that modulate the activity of enzyme proteins, particularly members of the trans-prenyltransferase subfamily (see Background of the Invention). The structural and functional information provided in the Background and Figures provide specific and substantial uses for the molecules of the present invention, particularly in combination with the expression information provided in FIG. 1. Experimental data as provided in FIG. 1 indicates expression in humans in the T cells from T cell leukemia, B cells from Burkitt lymphoma, neuroblastoma cells, duodenal adenocarcinoma cell line, adenocarcinoma cell line, stomach, breast, whole liver. Such uses can readily be determined using the information provided herein, that which is known in the art, and routine experimentation.

The proteins of the present invention (including variants and fragments that may have been disclosed prior to the present invention) are useful for biological assays related to enzymes that are related to members of the trans-prenyltransferase subfamily. Such assays involve any of the known enzyme functions or activities or properties useful for diagnosis and treatment of enzyme-related conditions that are specific for the subfamily of enzymes that the one of the present invention belongs to, particularly in cells and tissues that express the enzyme. Experimental data as provided in FIG. 1 indicates that the enzymes of the present invention are expressed in humans in the T cells from T cell leukemia, B cells from Burkitt lymphoma, neuroblastoma cells, duodenal adenocarcinoma cell line, adenocarcinoma cell line, stomach and breast detected by a virtual northern blot. In addition, PCR-based tissue screening panels indicate expression in whole liver.

The proteins of the present invention are also useful in drug screening assays, in cell-based or cell-free systems. Cell-based systems can be native, i.e., cells that normally express the enzyme, as a biopsy or expanded in cell culture. Experimental data as provided in FIG. 1 indicates expression in humans in the T cells from T cell leukemia, B cells from Burkitt lymphoma, neuroblastoma cells, duodenal adenocarcinoma cell line, adenocarcinoma cell line, stomach, breast, whole liver. In an alternate embodiment, cell-based assays involve recombinant host cells expressing the enzyme protein.

The polypeptides can be used to identify compounds that modulate enzyme activity of the protein in its natural state or an altered form that causes a specific disease or pathology associated with the enzyme. Both the enzymes of the present invention and appropriate variants and fragments can be used in high-throughput screens to assay candidate compounds for the ability to bind to the enzyme. These compounds can be further screened against a functional enzyme to determine the effect of the compound on the enzyme activity. Further, these compounds can be tested in animal or invertebrate systems to determine activity/effectiveness. Compounds can be identified that activate (agonist) or inactivate (antagonist) the enzyme to a desired degree.

Further, the proteins of the present invention can be used to screen a compound for the ability to stimulate or inhibit interaction between the enzyme protein and a molecule that normally interacts with the enzyme protein, e.g. a substrate or a component of the signal pathway that the enzyme protein normally interacts (for example, another enzyme). Such assays typically include the steps of combining the enzyme protein with a candidate compound under conditions that allow the enzyme protein, or fragment, to interact with the target molecule, and to detect the formation of a complex between the protein and the target or to detect the biochemical consequence of the interaction with the enzyme protein and the target, such as any of the associated effects of signal transduction such as protein phosphorylation, cAMP turnover, and adenylate cyclase activation, etc.

Candidate compounds include, for example, 1) peptides such as soluble peptides, including Ig-tailed fusion peptides and members of random peptide libraries (see, e.g., Lam et al., Nature 354:82-84 (1991); Houghten et al., Nature 354:84-86 (1991)) and combinatorial chemistry-derived molecular libraries made of D- and/or L-configuration amino acids; 2) phosphopeptides (e.g., members of random and partially degenerate, directed phosphopeptide libraries, see, e.g., Songyang et al., Cell 72:767-778 (1993)); 3) antibodies (e.g., polyclonal, monoclonal, humanized, anti-idiotypic, chimeric, and single chain antibodies as well as Fab, F(ab′)₂, Fab expression library fragments, and epitope-binding fragments of antibodies); and 4) small organic and inorganic molecules (e.g., molecules obtained from combinatorial and natural product libraries).

One candidate compound is a soluble fragment of the receptor that competes for substrate binding. Other candidate compounds include mutant enzymes or appropriate fragments containing mutations that affect enzyme function and thus compete for substrate. Accordingly, a fragment that competes for substrate, for example with a higher affinity, or a fragment that binds substrate but does not allow release, is encompassed by the invention.

The invention further includes other end point assays to identify compounds that modulate (stimulate or inhibit) enzyme activity. The assays typically involve an assay of events in the signal transduction pathway that indicate enzyme activity. Thus, the phosphorylation of a substrate, activation of a protein, a change in the expression of genes that are up- or down-regulated in response to the enzyme protein dependent signal cascade can be assayed.

Any of the biological or biochemical functions mediated by the enzyme can be used as an endpoint assay. These include all of the biochemical or biochemical/biological events described herein, in the references cited herein, incorporated by reference for these endpoint assay targets, and other functions known to those of ordinary skill in the art or that can be readily identified using the information provided in the Figures, particularly FIG. 2. Specifically, a biological function of a cell or tissues that expresses the enzyme can be assayed. Experimental data as provided in FIG. 1 indicates that the enzymes of the present invention are expressed in humans in the T cells from T cell leukemia, B cells from Burkitt lymphoma, neuroblastoma cells, duodenal adenocarcinoma cell line, adenocarcinoma cell line, stomach and breast detected by a virtual northern blot. In addition, PCR-based tissue screening panels indicate expression in whole liver.

Binding and/or activating compounds can also be screened by using chimeric enzyme proteins in which the amino terminal extracellular domain, or parts thereof, the entire transmembrane domain or subregions, such as any of the seven transmembrane segments or any of the intracellular or extracellular loops and the carboxy terminal intracellular domain, or parts thereof, can be replaced by heterologous domains or subregions. For example, a substrate-binding region can be used that interacts with a different substrate then that which is recognized by the native enzyme. Accordingly, a different set of signal transduction components is available as an end-point assay for activation. This allows for assays to be performed in other than the specific host cell from which the enzyme is derived.

The proteins of the present invention are also useful in competition binding assays in methods designed to discover compounds that interact with the enzyme (e.g. binding partners and/or ligands). Thus, a compound is exposed to a enzyme polypeptide under conditions that allow the compound to bind or to otherwise interact with the polypeptide. Soluble enzyme polypeptide is also added to the mixture. If the test compound interacts with the soluble enzyme polypeptide, it decreases the amount of complex formed or activity from the enzyme target. This type of assay is particularly useful in cases in which compounds are sought that interact with specific regions of the enzyme. Thus, the soluble polypeptide that competes with the target enzyme region is designed to contain peptide sequences corresponding to the region of interest.

To perform cell free drug screening assays, it is sometimes desirable to immobilize either the enzyme protein, or fragment, or its target molecule to facilitate separation of complexes from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay.

Techniques for immobilizing proteins on matrices can be used in the drug screening assays. In one embodiment, a fusion protein can be provided which adds a domain that allows the protein to be bound to a matrix. For example, glutathione-S-transferase fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, Mo.) or glutathione derivatized microtitre plates, which are then combined with the cell lysates (e.g., ³⁵S-labeled) and the candidate compound, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads are washed to remove any unbound label, and the matrix immobilized and radiolabel determined directly, or in the supernatant after the complexes are dissociated. Alternatively, the complexes can be dissociated from the matrix, separated by SDS-PAGE, and the level of enzyme-binding protein found in the bead fraction quantitated from the gel using standard electrophoretic techniques. For example, either the polypeptide or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin using techniques well known in the art. Alternatively, antibodies reactive with the protein but which do not interfere with binding of the protein to its target molecule can be derivatized to the wells of the plate, and the protein trapped in the wells by antibody conjugation. Preparations of a enzyme-binding protein and a candidate compound are incubated in the enzyme protein-presenting wells and the amount of complex trapped in the well can be quantitated. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the enzyme protein target molecule, or which are reactive with enzyme protein and compete with the target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the target molecule.

Agents that modulate one of the enzymes of the present invention can be identified using one or more of the above assays, alone or in combination. It is generally preferable to use a cell-based or cell free system first and then confirm activity in an animal or other model system. Such model systems are well known in the art and can readily be employed in this context.

Modulators of enzyme protein activity identified according to these drug screening assays can be used to treat a subject with a disorder mediated by the enzyme pathway, by treating cells or tissues that express the enzyme. Experimental data as provided in FIG. 1 indicates expression in humans in the T cells from T cell leukemia, B cells from Burkitt lymphoma, neuroblastoma cells, duodenal adenocarcinoma cell line, adenocarcinoma cell line, stomach, breast, whole liver. These methods of treatment include the steps of administering a modulator of enzyme activity in a pharmaceutical composition to a subject in need of such treatment, the modulator being identified as described herein.

In yet another aspect of the invention, the enzyme proteins can be used as “bait proteins” in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Pat. No. 5,283,317; Zervos et al. (1993) Cell 72:223-232; Madura et al. (1993) J. Biol. Chem. 268:12046-12054; Bartel et al. (1993) Biotechniques 14:920-924; Iwabuchi et al. (1993) Oncogene 8:1693-1696; and Brent WO94/10300), to identify other proteins, which bind to or interact with the enzyme and are involved in enzyme activity. Such enzyme-binding proteins are also likely to be involved in the propagation of signals by the enzyme proteins or enzyme targets as, for example, downstream elements of a enzyme-mediated signaling pathway. Alternatively, such enzyme-binding proteins are likely to be enzyme inhibitors.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for a enzyme protein is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein (“prey” or “sample”) is fused to a gene that codes for the activation domain of the known transcription factor. If the “bait” and the “prey” proteins are able to interact, in vivo, forming a enzyme-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene which encodes the protein which interacts with the enzyme protein.

This invention further pertains to novel agents identified by the above-described screening assays. Accordingly, it is within the scope of this invention to further use an agent identified as described herein in an appropriate animal model. For example, an agent identified as described herein (e.g., a enzyme-modulating agent, an antisense enzyme nucleic acid molecule, a enzyme-specific antibody, or a enzyme-binding partner) can be used in an animal or other model to determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent identified as described herein can be used in an animal or other model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein.

The enzyme proteins of the present invention are also useful to provide a target for diagnosing a disease or predisposition to disease mediated by the peptide. Accordingly, the invention provides methods for detecting the presence, or levels of, the protein (or encoding mRNA) in a cell, tissue, or organism. Experimental data as provided in FIG. 1 indicates expression in humans in the T cells from T cell leukemia, B cells from Burkitt lymphoma, neuroblastoma cells, duodenal adenocarcinoma cell line, adenocarcinoma cell line, stomach, breast, whole liver. The method involves contacting a biological sample with a compound capable of interacting with the enzyme protein such that the interaction can be detected. Such an assay can be provided in a single detection format or a multi-detection format such as an antibody chip array.

One agent for detecting a protein in a sample is an antibody capable of selectively binding to protein. A biological sample includes tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject.

The peptides of the present invention also provide targets for diagnosing active protein activity, disease, or predisposition to disease, in a patient having a variant peptide, particularly activities and conditions that are known for other members of the family of proteins to which the present one belongs. Thus, the peptide can be isolated from a biological sample and assayed for the presence of a genetic mutation that results in aberrant peptide. This includes amino acid substitution, deletion, insertion, rearrangement, (as the result of aberrant splicing events), and inappropriate post-translational modification. Analytic methods include altered electrophoretic mobility, altered tryptic peptide digest, altered enzyme activity in cell-based or cell-free assay, alteration in substrate or antibody-binding pattern, altered isoelectric point, direct amino acid sequencing, and any other of the known assay techniques useful for detecting mutations in a protein. Such an assay can be provided in a single detection format or a multi-detection format such as an antibody chip array.

In vitro techniques for detection of peptide include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence using a detection reagent, such as an antibody or protein binding agent. Alternatively, the peptide can be detected in vivo in a subject by introducing into the subject a labeled anti-peptide antibody or other types of detection agent. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques. Particularly useful are methods that detect the allelic variant of a peptide expressed in a subject and methods which detect fragments of a peptide in a sample.

The peptides are also useful in pharmacogenomic analysis. Pharmacogenomics deal with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See, e.g., Eichelbaum, M. (Clin. Exp. Phannacol. Physiol. 23(10-11):983-985. (1996)), and Linder, M. W. (Clin. Chem. 43(2):254-266 (1997)). The clinical outcomes of these variations result in severe toxicity of therapeutic drugs in certain individuals or therapeutic failure of drugs in certain individuals as a result of individual variation in metabolism. Thus, the genotype of the individual can determine the way a therapeutic compound acts on the body or the way the body metabolizes the compound. Further, the activity of drug metabolizing enzymes effects both the intensity and duration of drug action. Thus, the pharmacogenomics of the individual permit the selection of effective compounds and effective dosages of such compounds for prophylactic or therapeutic treatment based on the individual's genotype. The discovery of genetic polymorphisms in some drug metabolizing enzymes has explained why some patients do not obtain the expected drug effects, show an exaggerated drug effect, or experience serious toxicity from standard drug dosages. Polymorphisms can be expressed in the phenotype of the extensive metabolizer and the phenotype of the poor metabolizer. Accordingly, genetic polymorphism may lead to allelic protein variants of the enzyme protein in which one or more of the enzyme functions in one population is different from those in another population. The peptides thus allow a target to ascertain a genetic predisposition that can affect treatment modality. Thus, in a ligand-based treatment, polymorphism may give rise to amino terminal extracellular domains and/or other substrate-binding regions that are more or less active in substrate binding, and enzyme activation. Accordingly, substrate dosage would necessarily be modified to maximize the therapeutic effect within a given population containing a polymorphism. As an alternative to genotyping, specific polymorphic peptides could be identified.

The peptides are also useful for treating a disorder characterized by an absence of, inappropriate, or unwanted expression of the protein. Experimental data as provided in FIG. 1 indicates expression in humans in the T cells from T cell leukemia, B cells from Burkitt lymphoma, neuroblastoma cells, duodenal adenocarcinoma cell line, adenocarcinoma cell line, stomach, breast, whole liver. Accordingly, methods for treatment include the use of the enzyme protein or fragments.

Antibodies

The invention also provides antibodies that selectively bind to one of the peptides of the present invention, a protein comprising such a peptide, as well as variants and fragments thereof. As used herein, an antibody selectively binds a target peptide when it binds the target peptide and does not significantly bind to unrelated proteins. An antibody is still considered to selectively bind a peptide even if it also binds to other proteins that are not substantially homologous with the target peptide so long as such proteins share homology with a fragment or domain of the peptide target of the antibody. In this case, it would be understood that antibody binding to the peptide is still selective despite some degree of cross-reactivity.

As used herein, an antibody is defined in terms consistent with that recognized within the art: they are multi-subunit proteins produced by a mammalian organism in response to an antigen challenge. The antibodies of the present invention include polyclonal antibodies and monoclonal antibodies, as well as fragments of such antibodies, including, but not limited to, Fab or F(ab′)₂, and Fv fragments.

Many methods are known for generating and/or identifying antibodies to a given target peptide. Several such methods are described by Harlow, Antibodies, Cold Spring Harbor Press, (1989).

In general, to generate antibodies, an isolated peptide is used as an immunogen and is administered to a mammalian organism, such as a rat, rabbit or mouse. The full-length protein, an antigenic peptide fragment or a fusion protein can be used. Particularly important fragments are those covering functional domains, such as the domains identified in FIG. 2, and domain of sequence homology or divergence amongst the family, such as those that can readily be identified using protein alignment methods and as presented in the Figures.

Antibodies are preferably prepared from regions or discrete fragments of the enzyme proteins. Antibodies can be prepared from any region of the peptide as described herein. However, preferred regions will include those involved in function/activity and/or enzyme/binding partner interaction. FIG. 2 can be used to identify particularly important regions while sequence alignment can be used to identify conserved and unique sequence fragments.

An antigenic fragment will typically comprise at least 8 contiguous amino acid residues. The antigenic peptide can comprise, however, at least 10, 12, 14, 16 or more amino acid residues. Such fragments can be selected on a physical property, such as fragments correspond to regions that are located on the surface of the protein, e.g., hydrophilic regions or can be selected based on sequence uniqueness (see FIG. 2).

Detection on an antibody of the present invention can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ¹²⁵I, ¹³¹I, ³⁵S or ³H.

Antibody Uses

The antibodies can be used to isolate one of the proteins of the present invention by standard techniques, such as affinity chromatography or immunoprecipitation. The antibodies can facilitate the purification of the natural protein from cells and recombinantly produced protein expressed in host cells. In addition, such antibodies are useful to detect the presence of one of the proteins of the present invention in cells or tissues to determine the pattern of expression of the protein among various tissues in an organism and over the course of normal development. Experimental data as provided in FIG. 1 indicates that the enzymes of the present invention are expressed in humans in the T cells from T cell leukemia, B cells from Burkitt lymphoma, neuroblastoma cells, duodenal adenocarcinoma cell line, adenocarcinoma cell line, stomach and breast detected by a virtual northern blot. In addition, PCR-based tissue screening panels indicate expression in whole liver. Further, such antibodies can be used to detect protein in situ, in vitro, or in a cell lysate or supernatant in order to evaluate the abundance and pattern of expression. Also, such antibodies can be used to assess abnormal tissue distribution or abnormal expression during development or progression of a biological condition. Antibody detection of circulating fragments of the full length protein can be used to identify turnover.

Further, the antibodies can be used to assess expression in disease states such as in active stages of the disease or in an individual with a predisposition toward disease related to the protein's function. When a disorder is caused by an inappropriate tissue distribution, developmental expression, level of expression of the protein, or expressed/processed form, the antibody can be prepared against the normal protein. Experimental data as provided in FIG. 1 indicates expression in humans in the T cells from T cell leukemia, B cells from Burkitt lymphoma, neuroblastoma cells, duodenal adenocarcinoma cell line, adenocarcinoma cell line, stomach, breast, whole liver. If a disorder is characterized by a specific mutation in the protein, antibodies specific for this mutant protein can be used to assay for the presence of the specific mutant protein.

The antibodies can also be used to assess normal and aberrant subcellular localization of cells in the various tissues in an organism. Experimental data as provided in FIG. 1 indicates expression in humans in the T cells from T cell leukemia, B cells from Burkitt lymphoma, neuroblastoma cells, duodenal adenocarcinoma cell line, adenocarcinoma cell line, stomach, breast, whole liver. The diagnostic uses can be applied, not only in genetic testing, but also in monitoring a treatment modality. Accordingly, where treatment is ultimately aimed at correcting expression level or the presence of aberrant sequence and aberrant tissue distribution or developmental expression, antibodies directed against the protein or relevant fragments can be used to monitor therapeutic efficacy.

Additionally, antibodies are useful in pharmacogenomic analysis. Thus, antibodies prepared against polymorphic proteins can be used to identify individuals that require modified treatment modalities. The antibodies are also useful as diagnostic tools as an immunological marker for aberrant protein analyzed by electrophoretic mobility, isoelectric point, tryptic peptide digest, and other physical assays known to those in the art.

The antibodies are also useful for tissue typing. Experimental data as provided in FIG. 1 indicates expression in humans in the T cells from T cell leukemia, B cells from Burkitt lymphoma, neuroblastoma cells, duodenal adenocarcinoma cell line, adenocarcinoma cell line, stomach, breast, whole liver. Thus, where a specific protein has been correlated with expression in a specific tissue, antibodies that are specific for this protein can be used to identify a tissue type.

The antibodies are also useful for inhibiting protein function, for example, blocking the binding of the enzyme peptide to a binding partner such as a substrate. These uses can also be applied in a therapeutic context in which treatment involves inhibiting the protein's function. An antibody can be used, for example, to block binding, thus modulating (agonizing or antagonizing) the peptides activity. Antibodies can be prepared against specific fragments containing sites required for function or against intact protein that is associated with a cell or cell membrane. See FIG. 2 for structural information relating to the proteins of the present invention.

The invention also encompasses kits for using antibodies to detect the presence of a protein in a biological sample. The kit can comprise antibodies such as a labeled or labelable antibody and a compound or agent for detecting protein in a biological sample; means for determining the amount of protein in the sample; means for comparing the amount of protein in the sample with a standard; and instructions for use. Such a kit can be supplied to detect a single protein or epitope or can be configured to detect one of a multitude of epitopes, such as in an antibody detection array. Arrays are described in detail below for nuleic acid arrays and similar methods have been developed for antibody arrays.

Nucleic Acid Molecules

The present invention further provides isolated nucleic acid molecules that encode a enzyme peptide or protein of the present invention (cDNA, transcript and genomic sequence). Such nucleic acid molecules will consist of, consist essentially of, or comprise a nucleotide sequence that encodes one of the enzyme peptides of the present invention, an allelic variant thereof, or an ortholog or paralog thereof.

As used herein, an “isolated” nucleic acid molecule is one that is separated from other nucleic acid present in the natural source of the nucleic acid. Preferably, an “isolated” nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5′ and 3′ ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. However, there can be some flanking nucleotide sequences, for example up to about 5 KB, 4 KB, 3 KB, 2 KB, or 1 KB or less, particularly contiguous peptide encoding sequences and peptide encoding sequences within the same gene but separated by introns in the genomic sequence. The important point is that the nucleic acid is isolated from remote and unimportant flanking sequences such that it can be subjected to the specific manipulations described herein such as recombinant expression, preparation of probes and primers, and other uses specific to the nucleic acid sequences.

Moreover, an “isolated” nucleic acid molecule, such as a transcript/cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or chemical precursors or other chemicals when chemically synthesized. However, the nucleic acid molecule can be fused to other coding or regulatory sequences and still be considered isolated.

For example, recombinant DNA molecules contained in a vector are considered isolated. Further examples of isolated DNA molecules include recombinant DNA molecules maintained in heterologous host cells or purified (partially or substantially) DNA molecules in solution. Isolated RNA molecules include in vivo or in vitro RNA transcripts of the isolated DNA molecules of the present invention. Isolated nucleic acid molecules according to the present invention further include such molecules produced synthetically.

Accordingly, the present invention provides nucleic acid molecules that consist of the nucleotide sequence shown in FIG. 1 or 3 (SEQ ID NO: 1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in FIG. 2, SEQ ID NO:2. A nucleic acid molecule consists of a nucleotide sequence when the nucleotide sequence is the complete nucleotide sequence of the nucleic acid molecule.

The present invention further provides nucleic acid molecules that consist essentially of the nucleotide sequence shown in FIG. 1 or 3 (SEQ ID NO:1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in FIG. 2, SEQ ID NO:2. A nucleic acid molecule consists essentially of a nucleotide sequence when such a nucleotide sequence is present with only a few additional nucleic acid residues in the final nucleic acid molecule.

The present invention further provides nucleic acid molecules that comprise the nucleotide sequences shown in FIG. 1 or 3 (SEQ ID NO: 1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in FIG. 2, SEQ ID. NO:2. A nucleic acid molecule comprises a nucleotide sequence when the nucleotide sequence is at least part of the final nucleotide sequence of the nucleic acid molecule. In such a fashion, the nucleic acid molecule can be only the nucleotide sequence or have additional nucleic acid residues, such as nucleic acid residues that are naturally associated with it or heterologous nucleotide sequences. Such a nucleic acid molecule can have a few additional nucleotides or can comprises several hundred or more additional nucleotides. A brief description of how various types of these nucleic acid molecules can be readily made/isolated is provided below.

In FIGS. 1 and 3, both coding and non-coding sequences are provided. Because of the source of the present invention, humans genomic sequence (FIG. 3) and cDNA/transcript sequences (FIG. 1), the nucleic acid molecules in the Figures will contain genomic intronic sequences, 5′ and 3′ non-coding sequences, gene regulatory regions and non-coding intergenic sequences. In general such sequence features are either noted in FIGS. 1 and 3 or can readily be identified using computational tools known in the art. As discussed below, some of the non-coding regions, particularly gene regulatory elements such as promoters, are useful for a variety of purposes, e.g. control of heterologous gene expression, target for identifying gene activity modulating compounds, and are particularly claimed as fragments of the genomic sequence provided herein.

The isolated nucleic acid molecules can encode the mature protein plus additional amino or carboxyl-terminal amino acids, or amino acids interior to the mature peptide (when the mature form has more than one peptide chain, for instance). Such sequences may play a role in processing of a protein from precursor to a mature form, facilitate protein trafficking, prolong or shorten protein half-life or facilitate manipulation of a protein for assay or production, among other things. As generally is the case in situ, the additional amino acids may be processed away from the mature protein by cellular enzymes.

As mentioned above, the isolated nucleic acid molecules include, but are not limited to, the sequence encoding the enzyme peptide alone, the sequence encoding the mature peptide and additional coding sequences, such as a leader or secretory sequence (e.g., a pre-pro or pro-protein sequence), the sequence encoding the mature peptide, with or without the additional coding sequences, plus additional non-coding sequences, for example introns and non-coding 5′ and 3′ sequences such as transcribed but non-translated sequences that play a role in transcription, mRNA processing (including splicing and polyadenylation signals), ribosome binding and stability of mRNA. In addition, the nucleic acid molecule may be fused to a marker sequence encoding, for example, a peptide that facilitates purification.

Isolated nucleic acid molecules can be in the form of RNA, such as mRNA, or in the form DNA, including cDNA and genomic DNA obtained by cloning or produced by chemical synthetic techniques or by a combination thereof. The nucleic acid, especially DNA, can be double-stranded or single-stranded. Single-stranded nucleic acid can be the coding strand (sense strand) or the non-coding strand (anti-sense strand).

The invention further provides nucleic acid molecules that encode fragments of the peptides of the present invention as well as nucleic acid molecules that encode obvious variants of the enzyme proteins of the present invention that are described above. Such nucleic acid molecules may be naturally occurring, such as allelic variants (same locus), paralogs (different locus), and orthologs (different organism), or may be constructed by recombinant DNA methods or by chemical synthesis. Such non-naturally occurring variants may be made by mutagenesis techniques, including those applied to nucleic acid molecules, cells, or organisms. Accordingly, as discussed above, the variants can contain nucleotide substitutions, deletions, inversions and insertions. Variation can occur in either or both the coding and non-coding regions. The variations can produce both conservative and non-conservative amino acid substitutions.

The present invention further provides non-coding fragments of the nucleic acid molecules provided in FIGS. 1 and 3. Preferred non-coding fragments include, but are not limited to, promoter sequences, enhancer sequences, gene modulating sequences and gene termination sequences. Such fragments are useful in controlling heterologous gene expression and in developing screens to identify gene-modulating agents. A promoter can readily be identified as being 5′ to the ATG start site in the genomic sequence provided in FIG. 3.

A fragment comprises a contiguous nucleotide sequence greater than 12 or more nucleotides. Further, a fragment could at least 30, 40, 50, 100, 250 or 500 nucleotides in length. The length of the fragment will be based on its intended use. For example, the fragment can encode epitope bearing regions of the peptide, or can be useful as DNA probes and primers. Such fragments can be isolated using the known nucleotide sequence to synthesize an oligonucleotide probe. A labeled probe can then be used to screen a cDNA library, genomic DNA library, or mRNA to isolate nucleic acid corresponding to the coding region. Further, primers can be used in PCR reactions to clone specific regions of gene.

A probe/primer typically comprises substantially a purified oligonucleotide or oligonucleotide pair. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 20, 25, 40, 50 or more consecutive nucleotides.

Orthologs, homologs, and allelic variants can be identified using methods well known in the art. As described in the Peptide Section, these variants comprise a nucleotide sequence encoding a peptide that is typically 60-70%, 70-80%, 80-90%, and more typically at least about 90-95% or more homologous to the nucleotide sequence shown in the Figure sheets or a fragment of this sequence. Such nucleic acid molecules can readily be identified as being able to hybridize under moderate to stringent conditions, to the nucleotide sequence shown in the Figure sheets or a fragment of the sequence. Allelic variants can readily be determined by genetic locus of the encoding gene. As indicated by the data presented in FIG. 3, the map position was determined to be on chromosome 10 by ePCR.

FIG. 3 provides information on SNPs that have been found in the gene encoding the enzyme protein of the present invention. SNPs were identified at 57 different nucleotide positions in introns and regions 5′ and 3′ of the ORF. Such SNPs in introns and outside the ORF may affect control/regulatory elements.

As used herein, the term “hybridizes under stringent conditions” is intended to describe conditions for hybridization and washing under which nucleotide sequences encoding a peptide at least 60-70% homologous to each other typically remain hybridized to each other. The conditions can be such that sequences at least about 60%, at least about 70%, or at least about 80% or more homologous to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. One example of stringent hybridization conditions are hybridization in 6×sodium chloride/sodium citrate (SSC) at about 45C, followed by one or more washes in 0.2×SSC, 0.1% SDS at 50-65C. Examples of moderate to low stringency hybridization conditions are well known in the art.

Nucleic Acid Molecule Uses

The nucleic acid molecules of the present invention are useful for probes, primers, chemical intermediates, and in biological assays. The nucleic acid molecules are useful as a hybridization probe for messenger RNA, transcript/cDNA and genomic DNA to isolate full-length cDNA and genomic clones encoding the peptide described in FIG. 2 and to isolate cDNA and genomic clones that correspond to variants (alleles, orthologs, etc.) producing the same or related peptides shown in FIG. 2. 57 SNPs, including 8 indels, have been identified in the gene encoding the enzyme protein provided by the present invention and are given in FIG. 3.

The probe can correspond to any sequence along the entire length of the nucleic acid molecules provided in the Figures. Accordingly, it could be derived from 5′ noncoding regions, the coding region, and 3′ noncoding regions. However, as discussed, fragments are not to be construed as encompassing fragments disclosed prior to the present invention.

The nucleic acid molecules are also useful as primers for PCR to amplify any given region of a nucleic acid molecule and are useful to synthesize antisense molecules of desired length and sequence.

The nucleic acid molecules are also useful for constructing recombinant vectors. Such vectors include expression vectors that express a portion of, or all of, the peptide sequences. Vectors also include insertion vectors, used to integrate into another nucleic acid molecule sequence, such as into the cellular genome, to alter in situ expression of a gene and/or gene product. For example, an endogenous coding sequence can be replaced via homologous recombination with all or part of the coding region containing one or more specifically introduced mutations.

The nucleic acid molecules are also useful for expressing antigenic portions of the proteins.

The nucleic acid molecules are also useful as probes for determining the chromosomal positions of the nucleic acid molecules by means of in situ hybridization methods. As indicated by the data presented in FIG. 3, the map position was determined to be on chromosome 10 by ePCR.

The nucleic acid molecules are also useful in making vectors containing the gene regulatory regions of the nucleic acid molecules of the present invention.

The nucleic acid molecules are also useful for designing ribozymes corresponding to all, or a part, of the mRNA produced from the nucleic acid molecules described herein.

The nucleic acid molecules are also useful for making vectors that express part, or all, of the peptides.

The nucleic acid molecules are also useful for constructing host cells expressing a part, or all, of the nucleic acid molecules and peptides.

The nucleic acid molecules are also useful for constructing transgenic animals expressing all, or a part, of the nucleic acid molecules and peptides.

The nucleic acid molecules are also useful as hybridization probes for determining the presence, level, form and distribution of nucleic acid expression. Experimental data as provided in FIG. 1 indicates that the enzymes of the present invention are expressed in humans in the T cells from T cell leukemia, B cells from Burkitt lymphoma, neuroblastoma cells, duodenal adenocarcinoma cell line, adenocarcinoma cell line, stomach and breast detected by a virtual northern blot. In addition, PCR-based tissue screening panels indicate expression in whole liver. Accordingly, the probes can be used to detect the presence of, or to determine levels of, a specific nucleic acid molecule in cells, tissues, and in organisms. The nucleic acid whose level is determined can be DNA or RNA. Accordingly, probes corresponding to the peptides described herein can be used to assess expression and/or gene copy number in a given cell, tissue, or organism. These uses are relevant for diagnosis of disorders involving an increase or decrease in enzyme protein expression relative to normal results.

In vitro techniques for detection of mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detecting DNA includes Southern hybridizations and in situ hybridization.

Probes can be used as a part of a diagnostic test kit for identifying cells or tissues that express a enzyme protein, such as by measuring a level of a enzyme-encoding nucleic acid in a sample of cells from a subject e.g., mRNA or genomic DNA, or determining if a enzyme gene has been mutated. Experimental data as provided in FIG. 1 indicates that the enzymes of the present invention are expressed in humans in the T cells from T cell leukemia, B cells from Burkitt lymphoma, neuroblastoma cells, duodenal adenocarcinoma cell line, adenocarcinoma cell line, stomach and breast detected by a virtual northern blot. In addition, PCR-based tissue screening panels indicate expression in whole liver.

Nucleic acid expression assays are useful for drug screening to identify compounds that modulate enzyme nucleic acid expression.

The invention thus provides a method for identifying a compound that can be used to treat a disorder associated with nucleic acid expression of the enzyme gene, particularly biological and pathological processes that are mediated by the enzyme in cells and tissues that express it. Experimental data as provided in FIG. 1 indicates expression in humans in the T cells from T cell leukemia, B cells from Burkitt lymphoma, neuroblastoma cells, duodenal adenocarcinoma cell line, adenocarcinoma cell line, stomach, breast, whole liver. The method typically includes assaying the ability of the compound to modulate the expression of the enzyme nucleic acid and thus identifying a compound that can be used to treat a disorder characterized by undesired enzyme nucleic acid expression. The assays can be performed in cell-based and cell-free systems. Cell-based assays include cells naturally expressing the enzyme nucleic acid or recombinant cells genetically engineered to express specific nucleic acid sequences.

The assay for enzyme nucleic acid expression can involve direct assay of nucleic acid levels, such as mRNA levels, or on collateral compounds involved in the signal pathway. Further, the expression of genes that are up- or down-regulated in response to the enzyme protein signal pathway can also be assayed. In this embodiment the regulatory regions of these genes can be operably linked to a reporter gene such as luciferase.

Thus, modulators of enzyme gene expression can be identified in a method wherein a cell is contacted with a candidate compound and the expression of mRNA determined. The level of expression of enzyme mRNA in the presence of the candidate compound is compared to the level of expression of enzyme mRNA in the absence of the candidate compound. The candidate compound can then be identified as a modulator of nucleic acid expression based on this comparison and be used, for example to treat a disorder characterized by aberrant nucleic acid expression. When expression of mRNA is statistically significantly greater in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of nucleic acid expression. When nucleic acid expression is statistically significantly less in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of nucleic acid expression.

The invention further provides methods of treatment, with the nucleic acid as a target, using a compound identified through drug screening as a gene modulator to modulate enzyme nucleic acid expression in cells and tissues that express the enzyme. Experimental data as provided in FIG. 1 indicates that the enzymes of the present invention are expressed in humans in the T cells from T cell leukemia, B cells from Burkitt lymphoma, neuroblastoma cells, duodenal adenocarcinoma cell line, adenocarcinoma cell line, stomach and breast detected by a virtual northern blot. In addition, PCR-based tissue screening panels indicate expression in whole liver. Modulation includes both up-regulation (i.e. activation or agonization) or down-regulation (suppression or antagonization) or nucleic acid expression.

Alternatively, a modulator for enzyme nucleic acid expression can be a small molecule or drug identified using the screening assays described herein as long as the drug or small molecule inhibits the enzyme nucleic acid expression in the cells and tissues that express the protein. Experimental data as provided in FIG. 1 indicates expression in humans in the T cells from T cell leukemia, B cells from Burkitt lymphoma, neuroblastoma cells, duodenal adenocarcinoma cell line, adenocarcinoma cell line, stomach, breast, whole liver.

The nucleic acid molecules are also useful for monitoring the effectiveness of modulating compounds on the expression or activity of the enzyme gene in clinical trials or in a treatment regimen. Thus, the gene expression pattern can serve as a barometer for the continuing effectiveness of treatment with the compound, particularly with compounds to which a patient can develop resistance. The gene expression pattern can also serve as a marker indicative of a physiological response of the affected cells to the compound. Accordingly, such monitoring would allow either increased administration of the compound or the administration of alternative compounds to which the patient has not become resistant. Similarly, if the level of nucleic acid expression falls below a desirable level, administration of the compound could be commensurately decreased.

The nucleic acid molecules are also useful in diagnostic assays for qualitative changes in enzyme nucleic acid expression, and particularly in qualitative changes that lead to pathology. The nucleic acid molecules can be used to detect mutations in enzyme genes and gene expression products such as mRNA. The nucleic acid molecules can be used as hybridization probes to detect naturally occurring genetic mutations in the enzyme gene and thereby to determine whether a subject with the mutation is at risk for a disorder caused by the mutation. Mutations include deletion, addition, or substitution of one or more nucleotides in the gene, chromosomal rearrangement, such as inversion or transposition, modification of genomic DNA, such as aberrant methylation patterns or changes in gene copy number, such as amplification. Detection of a mutated form of the enzyme gene associated with a dysfunction provides a diagnostic tool for an active disease or susceptibility to disease when the disease results from overexpression, underexpression, or altered expression of a enzyme protein.

Individuals carrying mutations in the enzyme gene can be detected at the nucleic acid level by a variety of techniques. FIG. 3 provides information on SNPs that have been found in the gene encoding the enzyme protein of the present invention. SNPs were identified at 57 different nucleotide positions in introns and regions 5′ and 3′ of the ORF. Such SNPs in introns and outside the ORF may affect control/regulatory elements. As indicated by the data presented in FIG. 3, the map position was determined to be on chromosome 10 by ePCR. Genomic DNA can be analyzed directly or can be amplified by using PCR prior to analysis. RNA or cDNA can be used in the same way. In some uses, detection of the mutation involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g. U.S. Pat. Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran et al., Science 241:1077-1080 (1988); and Nakazawa et al., PNAS 91:360-364 (1994)), the latter of which can be particularly useful for detecting point mutations in the gene (see Abravaya et al., Nucleic Acids Res. 23:675-682 (1995)). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers which specifically hybridize to a gene under conditions such that hybridization and amplification of the gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. Deletions and insertions can be detected by a change in size of the amplified product compared to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to normal RNA or antisense DNA sequences.

Alternatively, mutations in a enzyme gene can be directly identified, for example, by alterations in restriction enzyme digestion patterns determined by gel electrophoresis.

Further, sequence-specific ribozymes (U.S. Pat. No. 5,498,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site. Perfectly matched sequences can be distinguished from mismatched sequences by nuclease cleavage digestion assays or by differences in melting temperature.

Sequence changes at specific locations can also be assessed by nuclease protection assays such as RNase and S1 protection or the chemical cleavage method. Furthermore, sequence differences between a mutant enzyme gene and a wild-type gene can be determined by direct DNA sequencing. A variety of automated sequencing procedures can be utilized when performing the diagnostic assays (Naeve, C. W., (1995) Biotechniques 19:448), including sequencing by mass spectrometry (see, e.g., PCT International Publication No. WO 94/16101; Cohen et al., Adv. Chromatogr. 36:127-162 (1996); and Griffin et al., Appl. Biochem. Biotechnol. 38:147-159 (1993)).

Other methods for detecting mutations in the gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA duplexes (Myers et al., Science 230:1242 (1985)); Cotton et al., PNAS 85:4397 (1988); Saleeba et al., Meth. Enzymol. 217:286-295 (1992)), electrophoretic mobility of mutant and wild type nucleic acid is compared (Orita et al., PNAS 86:2766 (1989); Cotton et al., Mutat. Res. 285:125-144 (1993); and Hayashi et al., Genet. Anal. Tech. Appl. 9:73-79 (1992)), and movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (Myers et al., Nature 313:495 (1985)). Examples of other techniques for detecting point mutations include selective oligonucleotide hybridization, selective amplification, and selective primer extension.

The nucleic acid molecules are also useful for testing an individual for a genotype that while not necessarily causing the disease, nevertheless affects the treatment modality. Thus, the nucleic acid molecules can be used to study the relationship between an individual's genotype and the individual's response to a compound used for treatment (pharmacogenomic relationship). Accordingly, the nucleic acid molecules described herein can be used to assess the mutation content of the enzyme gene in an individual in order to select an appropriate compound or dosage regimen for treatment. FIG. 3 provides information on SNPs that have been found in the gene encoding the enzyme protein of the present invention. SNPs were identified at 57 different nucleotide positions in introns and regions 5′ and 3′ of the ORF. Such SNPs in introns and outside the ORF may affect control/regulatory elements.

Thus nucleic acid molecules displaying genetic variations that affect treatment provide a diagnostic target that can be used to tailor treatment in an individual. Accordingly, the production of recombinant cells and animals containing these polymorphisms allow effective clinical design of treatment compounds and dosage regimens.

The nucleic acid molecules are thus useful as antisense constructs to control enzyme gene expression in cells, tissues, and organisms. A DNA antisense nucleic acid molecule is designed to be complementary to a region of the gene involved in transcription, preventing transcription and hence production of enzyme protein. An antisense RNA or DNA nucleic acid molecule would hybridize to the mRNA and thus block translation of mRNA into enzyme protein.

Alternatively, a class of antisense molecules can be used to inactivate mRNA in order to decrease expression of enzyme nucleic acid. Accordingly, these molecules can treat a disorder characterized by abnormal or undesired enzyme nucleic acid expression. This technique involves cleavage by means of ribozymes containing nucleotide sequences complementary to one or more regions in the mRNA that attenuate the ability of the mRNA to be translated. Possible regions include coding regions and particularly coding regions corresponding to the catalytic and other functional activities of the enzyme protein, such as substrate binding.

The nucleic acid molecules also provide vectors for gene therapy in patients containing cells that are aberrant in enzyme gene expression. Thus, recombinant cells, which include the patient's cells that have been engineered ex vivo and returned to the patient, are introduced into an individual where the cells produce the desired enzyme protein to treat the individual.

The invention also encompasses kits for detecting the presence of a enzyme nucleic acid in a biological sample. Experimental data as provided in FIG. 1 indicates that the enzymes of the present invention are expressed in humans in the T cells from T cell leukemia, B cells from Burkitt lymphoma, neuroblastoma cells, duodenal adenocarcinoma cell line, adenocarcinoma cell line, stomach and breast detected by a virtual northern blot. In addition, PCR-based tissue screening panels indicate expression in whole liver. For example, the kit can comprise reagents such as a labeled or labelable nucleic acid or agent capable of detecting enzyme nucleic acid in a biological sample; means for determining the amount of enzyme nucleic acid in the sample; and means for comparing the amount of enzyme nucleic acid in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect enzyme protein mRNA or DNA.

Nucleic Acid Arrays

The present invention further provides nucleic acid detection kits, such as arrays or microarrays of nucleic acid molecules that are based on the sequence information provided in FIGS. 1 and 3 (SEQ ID NOS:1 and 3).

As used herein “Arrays” or “Microarrays” refers to an array of distinct polynucleotides or oligonucleotides synthesized on a substrate, such as paper, nylon or other type of membrane, filter, chip, glass slide, or any other suitable solid support. In one embodiment, the microarray is prepared and used according to the methods described in U.S. Pat. No. 5,837,832, Chee et al., PCT application WO95/11995 (Chee et al.), Lockhart, D. J. et al. (1996; Nat. Biotech. 14:1675-1680) and Schena, M. et al. (1996; Proc. Natl. Acad. Sci. 93:10614-10619), all of which are incorporated herein in their entirety by reference. In other embodiments, such arrays are produced by the methods described by Brown et al., U.S. Pat. No. 5,807,522.

The microarray or detection kit is preferably composed of a large number of unique, single-stranded nucleic acid sequences, usually either synthetic antisense oligonucleotides or fragments of cDNAs, fixed to a solid support. The oligonucleotides are preferably about 6-60 nucleotides in length, more preferably 15-30 nucleotides in length, and most preferably about 20-25 nucleotides in length. For a certain type of microarray or detection kit, it may be preferable to use oligonucleotides that are only 7-20 nucleotides in length. The microarray or detection kit may contain oligonucleotides that cover the known 5′, or 3′, sequence, sequential oligonucleotides which cover the full length sequence; or unique oligonucleotides selected from particular areas along the length of the sequence. Polynucleotides used in the microarray or detection kit may be oligonucleotides that are specific to a gene or genes of interest.

In order to produce oligonucleotides to a known sequence for a microarray or detection kit, the gene(s) of interest (or an ORF identified from the contigs of the present invention) is typically examined using a computer algorithm which starts at the 5′ or at the 3′ end of the nucleotide sequence. Typical algorithms will then identify oligomers of defined length that are unique to the gene, have a GC content within a range suitable for hybridization, and lack predicted secondary structure that may interfere with hybridization. In certain situations it may be appropriate to use pairs of oligonucleotides on a microarray or detection kit. The “pairs” will be identical, except for one nucleotide that preferably is located in the center of the sequence. The second oligonucleotide in the pair (mismatched by one) serves as a control. The number of oligonucleotide pairs may range from two to one million. The oligomers are synthesized at designated areas on a substrate using a light-directed chemical process. The substrate may be paper, nylon or other type of membrane, filter, chip, glass slide or any other suitable solid support.

In another aspect, an oligonucleotide may be synthesized on the surface of the substrate by using a chemical coupling procedure and an ink jet application apparatus, as described in PCT application WO95/251116 (Baldeschweiler et al.) which is incorporated herein in its entirety by reference. In another aspect, a “gridded” array analogous to a dot (or slot) blot may be used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV, mechanical or chemical bonding procedures. An array, such as those described above, may be produced by hand or by using available devices (slot blot or dot blot apparatus), materials (any suitable solid support), and machines (including robotic instruments), and may contain 8, 24, 96, 384, 1536, 6144 or more oligonucleotides, or any other number between two and one million which lends itself to the efficient use of commercially available instrumentation.

In order to conduct sample analysis using a microarray or detection kit, the RNA or DNA from a biological sample is made into hybridization probes. The mRNA is isolated, and cDNA is produced and used as a template to make antisense RNA (aRNA). The aRNA is amplified in the presence of fluorescent nucleotides, and labeled probes are incubated with the microarray or detection kit so that the probe sequences hybridize to complementary oligonucleotides of the microarray or detection kit. Incubation conditions are adjusted so that hybridization occurs with precise complementary matches or with various degrees of less complementarity. After removal of nonhybridized probes, a scanner is used to determine the levels and patterns of fluorescence. The scanned images are examined to determine degree of complementarity and the relative abundance of each oligonucleotide sequence on the microarray or detection kit. The biological samples may be obtained from any bodily fluids (such as blood, urine, saliva, phlegm, gastric juices, etc.), cultured cells, biopsies, or other tissue preparations. A detection system may be used to measure the absence, presence, and amount of hybridization for all of the distinct sequences simultaneously. This data may be used for large-scale correlation studies on the sequences, expression patterns, mutations, variants, or polymorphisms among samples.

Using such arrays, the present invention provides methods to identify the expression of the enzyme proteins/peptides of the present invention. In detail, such methods comprise incubating a test sample with one or more nucleic acid molecules and assaying for binding of the nucleic acid molecule with components within the test sample. Such assays will typically involve arrays comprising many genes, at least one of which is a gene of the present invention and or alleles of the enzyme gene of the present invention. FIG. 3 provides information on SNPs that have been found in the gene encoding the enzyme protein of the present invention. SNPs were identified at 57 different nucleotide positions in introns and regions 5′ and 3′ of the ORF. Such SNPs in introns and outside the ORF may affect control/regulatory elements.

Conditions for incubating a nucleic acid molecule with a test sample vary. Incubation conditions depend on the format employed in the assay, the detection methods employed, and the type and nature of the nucleic acid molecule used in the assay. One skilled in the art will recognize that any one of the commonly available hybridization, amplification or array assay formats can readily be adapted to employ the novel fragments of the Human genome disclosed herein. Examples of such assays can be found in Chard, T, An Introduction to Radioimmunoassay and Related Techniques, Elsevier Science Publishers, Amsterdam, The Netherlands (1986); Bullock, G. R. et al., Techniques in Immunocytochemistry, Academic Press, Orlando, Fla. Vol. 1 (1982), Vol. 2 (1983), Vol. 3 (1985); Tijssen, P., Practice and Theory of Enzyme Immunoassays: Laboratory Techniques in Biochemistry and Molecular Biology, Elsevier Science Publishers, Amsterdam, The Netherlands (1985).

The test samples of the present invention include cells, protein or membrane extracts of cells. The test sample used in the above-described method will vary based on the assay format, nature of the detection method and the tissues, cells or extracts used as the sample to be assayed. Methods for preparing nucleic acid extracts or of cells are well known in the art and can be readily be adapted in order to obtain a sample that is compatible with the system utilized.

In another embodiment of the present invention, kits are provided which contain the necessary reagents to carry out the assays of the present invention.

Specifically, the invention provides a compartmentalized kit to receive, in close confinement, one or more containers which comprises: (a) a first container comprising one of the nucleic acid molecules that can bind to a fragment of the Human genome disclosed herein; and (b) one or more other containers comprising one or more of the following: wash reagents, reagents capable of detecting presence of a bound nucleic acid.

In detail, a compartmentalized kit includes any kit in which reagents are contained in separate containers. Such containers include small glass containers, plastic containers, strips of plastic, glass or paper, or arraying material such as silica. Such containers allows one to efficiently transfer reagents from one compartment to another compartment such that the samples and reagents are not cross-contaminated, and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another. Such containers will include a container which will accept the test sample, a container which contains the nucleic acid probe, containers which contain wash reagents (such as phosphate buffered saline, Tris-buffers, etc.), and containers which contain the reagents used to detect the bound probe. One skilled in the art will readily recognize that the previously unidentified enzyme gene of the present invention can be routinely identified using the sequence information disclosed herein can be readily incorporated into one of the established kit formats which are well known in the art, particularly expression arrays.

Vectors/Host Cells

The invention also provides vectors containing the nucleic acid molecules described herein. The term “vector” refers to a vehicle, preferably a nucleic acid molecule, which can transport the nucleic acid molecules. When the vector is a nucleic acid molecule, the nucleic acid molecules are covalently linked to the vector nucleic acid. With this aspect of the invention, the vector includes a plasmid, single or double stranded phage, a single or double stranded RNA or DNA viral vector, or artificial chromosome, such as a BAC, PAC, YAC, OR MAC.

A vector can be maintained in the host cell as an extrachromosomal element where it replicates and produces additional copies of the nucleic acid molecules. Alternatively, the vector may integrate into the host cell genome and produce additional copies of the nucleic acid molecules when the host cell replicates.

The invention provides vectors for the maintenance (cloning vectors) or vectors for expression (expression vectors) of the nucleic acid molecules. The vectors can function in prokaryotic or eukaryotic cells or in both (shuttle vectors).

Expression vectors contain cis-acting regulatory regions that are operably linked in the vector to the nucleic acid molecules such that transcription of the nucleic acid molecules is allowed in a host cell. The nucleic acid molecules can be introduced into the host cell with a separate nucleic acid molecule capable of affecting transcription. Thus, the second nucleic acid molecule may provide a trans-acting factor interacting with the cis-regulatory control region to allow transcription of the nucleic acid molecules from the vector. Alternatively, a trans-acting factor may be supplied by the host cell. Finally, a trans-acting factor can be produced from the vector itself. It is understood, however, that in some embodiments, transcription and/or translation of the nucleic acid molecules can occur in a cell-free system.

The regulatory sequence to which the nucleic acid molecules described herein can be operably linked include promoters for directing mRNA transcription. These include, but are not limited to, the left promoter from bacteriophage λ, the lac, TRP, and TAC promoters from E. coli, the early and late promoters from SV40, the CMV immediate early promoter, the adenovirus early and late promoters, and retrovirus long-terminal repeats.

In addition to control regions that promote transcription, expression vectors may also include regions that modulate transcription, such as repressor binding sites and enhancers. Examples include the SV40 enhancer, the cytomegalovirus immediate early enhancer, polyoma enhancer, adenovirus enhancers, and retrovirus LTR enhancers.

In addition to containing sites for transcription initiation and control, expression vectors can also contain sequences necessary for transcription termination and, in the transcribed region a ribosome binding site for translation. Other regulatory control elements for expression include initiation and termination codons as well as polyadenylation signals. The person of ordinary skill in the art would be aware of the numerous regulatory sequences that are useful in expression vectors. Such regulatory sequences are described, for example, in Sambrook et al., Molecular Cloning: A Laboratory Manual. 2nd. ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1989).

A variety of expression vectors can be used to express a nucleic acid molecule. Such vectors include chromosomal, episomal, and virus-derived vectors, for example vectors derived from bacterial plasmids, from bacteriophage, from yeast episomes, from yeast chromosomal elements, including yeast artificial chromosomes, from viruses such as baculoviruses, papovaviruses such as SV40, Vaccinia viruses, adenoviruses, poxviruses, pseudorabies viruses, and retroviruses. Vectors may also be derived from combinations of these sources such as those derived from plasmid and bacteriophage genetic elements, e.g. cosmids and phagemids. Appropriate cloning and expression vectors for prokaryotic and eukaryotic hosts are described in Sambrook et al., Molecular Cloning: A Laboratory Manual. 2nd. ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1989).

The regulatory sequence may provide constitutive expression in one or more host cells (i.e. tissue specific) or may provide for inducible expression in one or more cell types such as by temperature, nutrient additive, or exogenous factor such as a hormone or other ligand. A variety of vectors providing for constitutive and inducible expression in prokaryotic and eukaryotic hosts are well known to those of ordinary skill in the art.

The nucleic acid molecules can be inserted into the vector nucleic acid by well-known methodology. Generally, the DNA sequence that will ultimately be expressed is joined to an expression vector by cleaving the DNA sequence and the expression vector with one or more restriction enzymes and then ligating the fragments together. Procedures for restriction enzyme digestion and ligation are well known to those of ordinary skill in the art.

The vector containing the appropriate nucleic acid molecule can be introduced into an appropriate host cell for propagation or expression using well-known techniques. Bacterial cells include, but are not limited to, E. coli, Streptomyces, and Salmonella typhimurium. Eukaryotic cells include, but are not limited to, yeast, insect cells such as Drosophila, animal cells such as COS and CHO cells, and plant cells.

As described herein, it may be desirable to express the peptide as a fusion protein. Accordingly, the invention provides fusion vectors that allow for the production of the peptides. Fusion vectors can increase the expression of a recombinant protein, increase the solubility of the recombinant protein, and aid in the purification of the protein by acting for example as a ligand for affinity purification. A proteolytic cleavage site may be introduced at the junction of the fusion moiety so that the desired peptide can ultimately be separated from the fusion moiety. Proteolytic enzymes include, but are not limited to, factor Xa, thrombin, and enteroenzyme. Typical fusion expression vectors include pGEX (Smith et al., Gene 67:31-40 (1988)), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein. Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amann et al., Gene 69:301-315 (1988)) and pET 11d (Studier et al., Gene Expression Technology: Methods in Enzymology 185:60-89 (1990)).

Recombinant protein expression can be maximized in host bacteria by providing a genetic background wherein the host cell has an impaired capacity to proteolytically cleave the recombinant protein. (Gottesman, S., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990) 119-128). Alternatively, the sequence of the nucleic acid molecule of interest can be altered to provide preferential codon usage for a specific host cell, for example E. coli. (Wada et al., Nucleic Acids Res. 20:2111-2118 (1992)).

The nucleic acid molecules can also be expressed by expression vectors that are operative in yeast. Examples of vectors for expression in yeast e.g., S. cerevisiae include pYepSec1 (Baldari, et al., EMBO J. 6:229-234 (1987)), pMFa (Kurjan et al., Cell 30:933-943(1982)), pJRY88 (Schultz et al., Gene 54:113-123 (1987)), and pYES² (Invitrogen Corporation, San Diego, Calif.).

The nucleic acid molecules can also be expressed in insect cells using, for example, baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf9 cells) include the pAc series (Smith et al., Mol. Cell Biol. 3:2156-2165 (1983)) and the pVL series (Lucklow et al., Virology 170:31-39 (1989)).

In certain embodiments of the invention, the nucleic acid molecules described herein are expressed in mammalian cells using mammalian expression vectors. Examples of mammalian expression vectors include pCDM8 (Seed, B. Nature 329:840(1987)) and pMT2PC (Kaufman et al., EMBO J. 6:187-195 (1987)).

The expression vectors listed herein are provided by way of example only of the well-known vectors available to those of ordinary skill in the art that would be useful to express the nucleic acid molecules. The person of ordinary skill in the art would be aware of other vectors suitable for maintenance propagation or expression of the nucleic acid molecules described herein. These are found for example in Sambrook, J., Fritsh, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.

The invention also encompasses vectors in which the nucleic acid sequences described herein are cloned into the vector in reverse orientation, but operably linked to a regulatory sequence that permits transcription of antisense RNA. Thus, an antisense transcript can be produced to all, or to a portion, of the nucleic acid molecule sequences described herein, including both coding and non-coding regions. Expression of this antisense RNA is subject to each of the parameters described above in relation to expression of the sense RNA (regulatory sequences, constitutive or inducible expression, tissue-specific expression).

The invention also relates to recombinant host cells containing the vectors described herein. Host cells therefore include prokaryotic cells, lower eukaryotic cells such as yeast, other eukaryotic cells such as insect cells, and higher eukaryotic cells such as mammalian cells.

The recombinant host cells are prepared by introducing the vector constructs described herein into the cells by techniques readily available to the person of ordinary skill in the art. These include, but are not limited to, calcium phosphate transfection, DEAE-dextran-mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, lipofection, and other techniques such as those found in Sambrook, et al. (Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989).

Host cells can contain more than one vector. Thus, different nucleotide sequences can be introduced on different vectors of the same cell. Similarly, the nucleic acid molecules can be introduced either alone or with other nucleic acid molecules that are not related to the nucleic acid molecules such as those providing trans-acting factors for expression vectors. When more than one vector is introduced into a cell, the vectors can be introduced independently, co-introduced or joined to the nucleic acid molecule vector.

In the case of bacteriophage and viral vectors, these can be introduced into cells as packaged or encapsulated virus by standard procedures for infection and transduction. Viral vectors can be replication-competent or replication-defective. In the case in which viral replication is defective, replication Will occur in host cells providing functions that complement the defects.

Vectors generally include selectable markers that enable the selection of the subpopulation of cells that contain the recombinant vector constructs. The marker can be contained in the same vector that contains the nucleic acid molecules described herein or may be on a separate vector. Markers include tetracycline or ampicillin-resistance genes for prokaryotic host cells and dihydrofolate reductase or neomycin resistance for eukaryotic host cells. However, any marker that provides selection for a phenotypic trait will be effective.

While the mature proteins can be produced in bacteria, yeast, mammalian cells, and other cells under the control of the appropriate regulatory sequences, cell-free transcription and translation systems can also be used to produce these proteins using RNA derived from the DNA constructs described herein.

Where secretion of the peptide is desired, which is difficult to achieve with multi-transmembrane domain containing proteins such as enzymes, appropriate secretion signals are incorporated into the vector. The signal sequence can be endogenous to the peptides or heterologous to these peptides.

Where the peptide is not secreted into the medium, which is typically the case with enzymes, the protein can be isolated from the host cell by standard disruption procedures, including freeze thaw, sonication, mechanical disruption, use of lysing agents and the like. The peptide can then be recovered and purified by well-known purification methods including ammonium sulfate precipitation, acid extraction, anion or cationic exchange chromatography, phosphocellulose chromatography, hydrophobic-interaction chromatography, affinity chromatography, hydroxylapatite chromatography, lectin chromatography, or high performance liquid chromatography.

It is also understood that depending upon the host cell in recombinant production of the peptides described herein, the peptides can have various glycosylation patterns, depending upon the cell, or maybe non-glycosylated as when produced in bacteria. In addition, the peptides may include an initial modified methionine in some cases as a result of a host-mediated process.

Uses of Vectors and Host Cells

The recombinant host cells expressing the peptides described herein have a variety of uses. First, the cells are useful for producing a enzyme protein or peptide that can be further purified to produce desired amounts of enzyme protein or fragments. Thus, host cells containing expression vectors are useful for peptide production.

Host cells are also useful for conducting cell-based assays involving the enzyme protein or enzyme protein fragments, such as those described above as well as other formats known in the art. Thus, a recombinant host cell expressing a native enzyme protein is useful for assaying compounds that stimulate or inhibit enzyme protein function.

Host cells are also useful for identifying enzyme protein mutants in which these functions are affected. If the mutants naturally occur and give rise to a pathology, host cells containing the mutations are useful to assay compounds that have a desired effect on the mutant enzyme protein (for example, stimulating or inhibiting function) which may not be indicated by their effect on the native enzyme protein.

Genetically engineered host cells can be further used to produce non-human transgenic animals. A transgenic animal is preferably a mammal, for example a rodent, such as a rat or mouse, in which one or more of the cells of the animal include a transgene. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal in one or more cell types or tissues of the transgenic animal. These animals are useful for studying the function of a enzyme protein and identifying and evaluating modulators of enzyme protein activity. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, and amphibians.

A transgenic animal can be produced by introducing nucleic acid into the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. Any of the enzyme protein nucleotide sequences can be introduced as a transgene into the genome of a non-human animal, such as a mouse.

Any of the regulatory or other sequences useful in expression vectors can form part of the transgenic sequence. This includes intronic sequences and polyadenylation signals, if not already included. A tissue-specific regulatory sequence(s) can be operably linked to the transgene to direct expression of the enzyme protein to particular cells.

Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Pat. Nos. 4,736,866 and 4,870,009, both by Leder et al., U.S. Pat. No. 4,873,191 by Wagner et al. and in Hogan, B., Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the transgene in its genome and/or expression of transgenic mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene can further be bred to other transgenic animals carrying other transgenes. A transgenic animal also includes animals in which the entire animal or tissues in the animal have been produced using the homologously recombinant host cells described herein.

In another embodiment, transgenic non-human animals can be produced which contain selected systems that allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P1. For a description of the cre/loxP recombinase system, see, e.g., Lakso et al. PNAS 89:6232-6236 (1992). Another example of a recombinase system is the FLP recombinase system of S. cerevisiae (O'Gorman et al. Science 251:1351-1355 (1991). If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein is required. Such animals can be provided through the construction of “double” transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, I. et al. Nature 385:810-813 (1997) and PCT International Publication Nos. WO 97/07668 and WO 97/07669. In brief, a cell, e.g., a somatic cell, from the transgenic animal can be isolated and induced to exit the growth cycle and enter G_(o) phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyst and then transferred to pseudopregnant female foster animal. The offspring born of this female foster animal will be a clone of the animal from which the cell, e.g., the somatic cell, is isolated.

Transgenic animals containing recombinant cells that express the peptides described herein are useful to conduct the assays described herein in an in vivo context. Accordingly, the various physiological factors that are present in vivo'and that could effect substrate binding, enzyme protein activation, and signal transduction, may not be evident from in vitro cell-free or cell-based assays. Accordingly, it is useful to provide non-human transgenic animals to assay in vivo enzyme protein function, including substrate interaction, the effect of specific mutant enzyme proteins on enzyme protein function and substrate interaction, and the effect of chimeric enzyme proteins. It is also possible to assess the effect of null mutations, that is, mutations that substantially or completely eliminate one or more enzyme protein functions.

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the above-described modes for carrying out the invention which are obvious to those skilled in the field of molecular biology or related fields are intended to be within the scope of the following claims.

                   #             SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 4 <210> SEQ ID NO 1 <211> LENGTH: 3433 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 1 ctccgcacgc ccctgccccg tcgcctcccg ggagcggctg cagtccccgt tg #gctgcaga     60 cgggcagaca cccgaagtgt ccgcgccggc agccggaccg caagcgatga at #atcgaacc    120 gcgctcccgg gcctggccga agcgcttcct gtgccaggtt tccggctccg gg #tcccggga    180 ggaggatcgc gggccattat gcggagccgc cgccctgccg cgactttcag ac #tccgacca    240 tggcctcgcg ctggtggcgg aggcggcgcg gctgctcctg gaagccggcg gc #gcggagcc    300 ccgggcccgg ctcccccggc cgtgcgggac cgttggggcc gatcgccgct gc #cgatattc    360 cgcgcgcagg ttcataggcg gaagggactt gacttgtctc agatacccta ta #ttaatctt    420 gtgaagcatt taacatctgc ctgtccaaat gtatgtcgta tatcacggtt tc #atcacaca    480 accccagaca gtaaaacaca cagtggtgaa aaatacaccg atcctttcaa ac #tcggttgg    540 agagacttga aaggtctgta tgaggacatt agaaaggaac tgcttatatc aa #catcagaa    600 cttaaggaaa tgtctgagta ctactttgat gggaaaggga aagcctttcg ac #caattatt    660 gtggcgctaa tggcccgagc atgcaatatt catcataaca actcccgaca tg #tgcaagcc    720 agccagcgcg ccatagcctt aattgcagaa atgatccaca ctgctagtct gg #ttcacgat    780 gacgttattg acgatgcaag ttctcgaaga ggaaaacaca cagttaataa ga #tctggggt    840 gaaaagaagg ctgttcttgc tggagattta attctttctg cagcatctat ag #ctctggca    900 cgaattggaa atacaactgt tatatctatt ttaacccaag ttattgaaga tt #tggtgcgt    960 ggtgaatttc ttcagctcgg gtcaaaagaa aatgagaatg aaagatttgc ac #actacctt   1020 gagaagacat tcaagaagac cgccagcctg atagccaaca gttgtaaagc ag #tctctgtt   1080 ctaggatgtc ccgacccagt ggtgcatgag atcgcctatc agtacggaaa aa #atgtagga   1140 atagcttttc agctaataga tgatgtattg gacttcacct cgtgttctga cc #agatgggc   1200 aaaccaacat cagctgatct gaagctcggg ttagccactg gtcctgtcct gt #ttgcctgt   1260 cagcaggtag gttttacaaa ctccctttga cacatcactg catagcccca ca #gaactgat   1320 gtcccgcggc acagctgatg ggaagattgc ataaaggaat agatgggaag gc #attcagat   1380 aagagatcac aggtctgcat ttgatcctgg ctgagtgaga tgttggggct gg #tcatttca   1440 ccttgctaag actgtttcct tatctgtaaa attgagaaga tcacctttct cc #cagggtgg   1500 ttgtgaggat tagctaagat cctatttgag atctttgtgt cttgtggtgt gc #cataggca   1560 tttgaggtag catcgtgatt atttccatat attttggcca ctggcaaagt ga #acggtttc   1620 taagtcttga ttataggact ggactttggt ggtcctcaga gccccttaaa ag #gcatagga   1680 agcatcaagg gcctccaagc ataagaaatt ctccggttct agaagtttaa tg #agactctg   1740 ctgctctgag agaggcttta gaacctcggc cattgcctca aaatgtcagg aa #gtcagtgg   1800 agtgcagtag acccacatag ttccttcttt ctccggattg agggactgag tc #ccccttaa   1860 tgtgaatgaa aggcttagga agcttcaaag atgttccctc gactgacaaa gc #agacattc   1920 tcacagcctc ctccagaccc tgccacatgg cttgtggctg tactgaatgt ta #cttgaaat   1980 aagtgagaca ttagctggtg ttggaacatc tcgttaatag attttcatct ta #gtagtatt   2040 taatttgtta tgttgcaaag cagtaagatg ttcatcaccg tgccatgaaa tt #caacatta   2100 gctctttggt gtaaaattat agtaactttt ggtctttcag agattttgcc tc #tattctgt   2160 cttcacgttt acaaaggtca gtcatgtcct ccataaaatt cagtgattcc ac #tgtgatac   2220 agaaaccacg gcccttgctt ttggtgggtt tctgattgga gagaggaaag gt #catctttc   2280 acccactatc tagcatagcc attggcagca tgattcttcc caggggaggc tg #acgttctg   2340 ggtggctgga ccaggctact ttggcagctt gctaaggcta tgaatggaga tg #ttggggta   2400 ctcggtagga acacccgccc tcattattac aaggcttcca tcctctcaaa ct #ttggaggc   2460 tgaggtaaga agtgaaaggt atgctgtaaa taggtcctct ctcccaatga gg #cttacttg   2520 ccagcccaaa atcaaagagt ataatacatg tgcccagttt tgacaaaaat tt #ataaaacc   2580 tccttttgta cattaaggca agagtgagga acatttgagc catgtaggtg tt #atgctggg   2640 gattagaaaa atgaggcact ggctaccagt aacctatata actgcgaaca tt #acttctca   2700 gatacttgtt agtaaacatg agtgaaggaa agcaagatgg actgagtgtg ct #gaaatcca   2760 gctagcttgg taaagattcc tttacctagg ctcagattat caggataaaa gg #aaaaagcc   2820 tttttccctg gagaagtcta tgagaaagtt ttggttgctc tatttgtaaa aa #tcttcaaa   2880 ttgttaagta cttgttatga accccaggat actaagttac cggttgagtc ct #acttaaac   2940 cttaaggtga ctgggtgaga ggaggctggc ctcttcggac tgtgtttcac tc #tgaatata   3000 tttcagaaga aactaactta ctttccccta cacacacaaa ggagtaatgg ct #atctctgc   3060 tttcatatat agtgggggaa aggggaaatg gacctctgca tagtatctgt ca #gtaatcta   3120 caagagactg aaaaatgctg gttaggcggt ggctcatgcc tgtaatccca gc #actttggg   3180 aggctgaggc agttggatta tgaggtcagg agttcaagac cagcctgacc aa #tatggtgg   3240 aaaccccgtc tctactaaaa atacaaaaat tagccgggcc tggtggtgca tg #cctgtaat   3300 cccagctact cgggaggcca aggaaggaga atccttgaac ctgggaggca ga #ggttgcag   3360 tgagccgaga ctgcactcca gcctgggtga cagagtgaga ctccgtctca aa #aaaaaaaa   3420 aaaaaaaaaa aaa               #                   #                   #    3433 <210> SEQ ID NO 2 <211> LENGTH: 363 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 2 Met Arg Ser Arg Arg Pro Ala Ala Thr Phe Ar #g Leu Arg Pro Trp Pro  1               5   #                10   #                15 Arg Ala Gly Gly Gly Gly Gly Ala Ala Ala Pr #o Gly Ser Arg Arg Arg             20       #            25       #            30 Gly Ala Pro Gly Pro Ala Pro Pro Ala Val Ar #g Asp Arg Trp Gly Arg         35           #        40           #        45 Ser Pro Leu Pro Ile Phe Arg Ala Gln Val Hi #s Arg Arg Lys Gly Leu     50               #    55               #    60 Asp Leu Ser Gln Ile Pro Tyr Ile Asn Leu Va #l Lys His Leu Thr Ser 65                   #70                   #75                   #80 Ala Cys Pro Asn Val Cys Arg Ile Ser Arg Ph #e His His Thr Thr Pro                 85   #                90   #                95 Asp Ser Lys Thr His Ser Gly Glu Lys Tyr Th #r Asp Pro Phe Lys Leu             100       #           105       #           110 Gly Trp Arg Asp Leu Lys Gly Leu Tyr Glu As #p Ile Arg Lys Glu Leu         115           #       120           #       125 Leu Ile Ser Thr Ser Glu Leu Lys Glu Met Se #r Glu Tyr Tyr Phe Asp     130               #   135               #   140 Gly Lys Gly Lys Ala Phe Arg Pro Ile Ile Va #l Ala Leu Met Ala Arg 145                 1 #50                 1 #55                 1 #60 Ala Cys Asn Ile His His Asn Asn Ser Arg Hi #s Val Gln Ala Ser Gln                 165   #               170   #               175 Arg Ala Ile Ala Leu Ile Ala Glu Met Ile Hi #s Thr Ala Ser Leu Val             180       #           185       #           190 His Asp Asp Val Ile Asp Asp Ala Ser Ser Ar #g Arg Gly Lys His Thr         195           #       200           #       205 Val Asn Lys Ile Trp Gly Glu Lys Lys Ala Va #l Leu Ala Gly Asp Leu     210               #   215               #   220 Ile Leu Ser Ala Ala Ser Ile Ala Leu Ala Ar #g Ile Gly Asn Thr Thr 225                 2 #30                 2 #35                 2 #40 Val Ile Ser Ile Leu Thr Gln Val Ile Glu As #p Leu Val Arg Gly Glu                 245   #               250   #               255 Phe Leu Gln Leu Gly Ser Lys Glu Asn Glu As #n Glu Arg Phe Ala His             260       #           265       #           270 Tyr Leu Glu Lys Thr Phe Lys Lys Thr Ala Se #r Leu Ile Ala Asn Ser         275           #       280           #       285 Cys Lys Ala Val Ser Val Leu Gly Cys Pro As #p Pro Val Val His Glu     290               #   295               #   300 Ile Ala Tyr Gln Tyr Gly Lys Asn Val Gly Il #e Ala Phe Gln Leu Ile 305                 3 #10                 3 #15                 3 #20 Asp Asp Val Leu Asp Phe Thr Ser Cys Ser As #p Gln Met Gly Lys Pro                 325   #               330   #               335 Thr Ser Ala Asp Leu Lys Leu Gly Leu Ala Th #r Gly Pro Val Leu Phe             340       #           345       #           350 Ala Cys Gln Gln Val Gly Phe Thr Asn Ser Le #u         355           #       360 <210> SEQ ID NO 3 <211> LENGTH: 39982 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 3 catcaatatg gcaagaaaat gtcttggagg gtacctaaca ctccaacctc aa #aacgacaa     60 ccttgatcgc tttcagttac acataggcca ttttgatcca tctgtactgg ct #cttttcat    120 ttgtctaagg gcagcaaaat agactaaagt tgttttcaga ctgcacaaga ga #agtctgtt    180 ctttagcact tacctgcata actcagatag tgtttttaac ttcctcaact ca #tgcttggc    240 ctagttgggt caaaagaact acttgtgaat tccgtatgtc caattggtag gt #tactgttt    300 tttctcaaga gtttagctat acagtaatgt tggaagtctt gaggaacttc ag #ctgctgtc    360 cctacttagc cttgcaatac tacggcatct tttcttcttt ttcttttttt ta #aagacgga    420 gtctcacttt gtcacctagg ccgaagtgca gtggcacaat ctcggctcac tg #caacctct    480 gcctcccagg ttcaagtgat tctcttgcct cagcctccta agtagttggg at #tacagaac    540 atgcaccacc atgcccaact aatttttaaa tatttagtag agacgggttt ca #ccatgttg    600 gccaggctgg tctcaaactc ctgacctcaa gtgatccacc tgcctcggcc tc #ccacagtg    660 ctgggattac aggctgagcc actgtgcccc cgacctacag catcttttta ag #agcaatgt    720 tttctgtttt aatgtggcca agcaatctct aaacgaacat ggtctgacaa aa #ttgtgtag    780 tgacatactt gacaactggg tgagcttgag tgtgatactt atttgaccat ac #ggtatttc    840 ctctatatgt ttccttatct ttatatacaa aaaagggcaa atgataatgt ct #tagtcata    900 ggatcaagta caacccaagt gcttactgct acactctact tggcaaattc ca #ccttatga    960 atgtttctta atatataaac ctaatctaaa ccaagataag ctacaggtgc at #attaacaa   1020 tctttactca taaagttttg catattttta catactattc ttcaagatgg aa #aaaacacc   1080 atcaaactgg cttattttca tagatgtctt tatatagtct atgatgtctt ca #ttccataa   1140 aaaatccaca cgattaaata tgaaattaat gtacccagct atgaggctac cg #cattcttt   1200 aacccaagaa caagaaaata catgaatcag agaactgcaa ttacctactt gc #tggtctat   1260 ttcctcatta gagtgaattt tttgaggact aaattgcatt tctctatctc ta #atgcttac   1320 cccctatctc actggctctg tgtgtttgag tgcatgcgct gaatgtttat at #cacttaat   1380 ttctgttcgg aacacgctgt ctcttagcac cagtagatct ggccttagag ct #aaggaaag   1440 aaggcctttc taacccataa ggggtactaa tcctgtacag actccaatat ct #cccgggct   1500 gggtacacgc aggttcacac ccaggtgtga gcaagattgc caaactatac ct #ataaggcg   1560 tttggaggag agagtccaaa agtcacgaga cccggctaat ttagctacta tt #tcacaaca   1620 accctgatcg tggtcggact tgtttctagg aagatgcgat gggctggaac tt #ccttcaag   1680 aacagattgc aaaaggcagc cgaccagggc gtgtcaggtc actgccaagg ga #agcagcag   1740 cggaaaccgt cgcctccggc ttaggctgcg gagcgggaac cccattctct ga #gttatgtt   1800 tctgcctaaa cacgcagaac aaaagagttc gtggctgcaa gggtggcgcg cg #gtagtatt   1860 tcttgctaat aaaaggtccc cacagggaca tttttgctat gactgcaggc gt #ggccagtg   1920 cccctgcaca gcttccggga agaggtgggg ataggaggct cgccccgggg aa #ggtcacgc   1980 tcggggtccc cagaccaggt ctccgcacgc ccctgccccg tcgcctcccg gg #agcggctg   2040 cagtccccgt tggctgcaga cgggcagaca cccgaagtgt ccgcgccggc ag #ccggaccg   2100 caagcgagga agagcgaacc gcgctcccgg gcctggccga agcgcttcct gt #gccaggtt   2160 tccggctccg ggtcccggga ggaggatcgc gggccagagg cggagccgcc gc #cctgccgc   2220 gactttcaga ctccgaccat ggcctcgcgc tggtggcggt ggcggcgcgg ct #gctcctgg   2280 aagccggcgg cgcggagccc cgggcccggc tcccccggcc gtgcgggacc gt #tggggccg   2340 agcgccgctg ccgaagtccg cgcgcaggtg aggttgggag gcgcgcgccc gg #cggggctc   2400 agaggtcacg gctccaatga cagcagtggg cggaatgaat gggagcgggg ag #cacgtgcg   2460 tcgcgacgcg ggggcgcgcg gggtagctcc ggggtagctc cggggtggga ct #ccggagct   2520 gaggggtgct cgcggtggga cggagccgcg cgttggactg aagtaggggc gc #cctacacg   2580 gggttgcaga aagcggtgtc ctggggaccc cgggagcgtt ttggggggtg ga #gaaagcgg   2640 tgggatccgt gtcctggggg aagcgcagga gcgatcagat tgaccgctgc ta #tatggaca   2700 aggttaatta agcctggaga gcgactgcag ctatttactt tggagttaga gg #aagacaga   2760 tcttgcctga aattttagag ccaaagtgct cagagctctc tccgagaaac gg #aggatcga   2820 atcggcctcg gaatagtccg aaaaggtctt gtggagaatg cagggctggt gc #tagggtgg   2880 accggacctt agttgtccag cagtggcttc gggaggagag cacacctgga tg #gggctgga   2940 atgacactgg aaggagaaag gcccgaggcc gtcaggagga gagaaaccct gg #agtcatct   3000 aaagtcagaa tctcagtgat agcccattct ttcagggtct cctctgctgc ct #ttgggttc   3060 cgatctcctt tttctccctt tctggtcagt ttagcccctg taaatggaca ct #gtgagccc   3120 ttctgcactt tgtaatgatt ctcagtgtgc catggggtag gcccatgcta tt #agcataac   3180 cgtgcaaaat ctatggactc actgttactt aagtttattt gaatttagta ct #cttttaat   3240 tcagatttgg tatactttat gtgtccgtgt tctcatcaaa catcatttcc ca #gtatgaaa   3300 tatataacac ttataaatat ctactttgta ccaaagtaga tgcgtatcac aa #attatcca   3360 aaacaaggct tgggccaggc acagtggctc acacctgtaa tcccagcact tt #gggaggct   3420 gaggtgggag aatcggttga ggccaggagt ttgggaccag cctaggcaac at #agcaagac   3480 tctgtctcta taaaaaatag aaaaaattca ccaggtgggg tggtgcatgc ct #gtagttct   3540 acctactcag gagcctgagg gaggaggatt gttcgatccc aggagttcaa ga #ttacagtg   3600 agctgtttat tgtgatagtg ccagtgcact ccagcctggg caacagtgtg ag #accctatc   3660 tctaaaaaat ctaaagcaaa aaagacgttt ggagaccaag tggcagctgg gc #aactagac   3720 aatgctagag agtaaagaga acagaatatg gggggtgagg ggcacgtggg ag #aagaggct   3780 tagaggagga aggtaggctt tgctgtgatc catttcagga ctgttctctc ca #gacttcag   3840 atatttctag ttccacagaa gaagccagta tttgaagaga tgggtgcatc ca #ccctctta   3900 tgccactaca tgcttcttct tcttcttctt tttttttttt ttttgacaca ga #gtctcact   3960 ctgtcgccca ggctggagtg cagtggcgga atctcggctc actgcaaact cc #acctccca   4020 ggttcaagcg attctcctgc tgcagactcc caagtagctg ggattacagg cg #tacaccac   4080 gacccccagc taatttttgt atttttagta gagacagcat ttcaccatgt tg #cccaggct   4140 ggtctggaac tcctgacctc aagtgatcca ccccctcctc ggcctcccaa ag #tgcgggga   4200 ttacaggtgt gagccaccac gcctggcctg acacttcttt ttaaaaaagt tt #cttgccca   4260 ccaagcaacc ttagccaggg aaagtgtgct tttctggaga gaatatgctt ta #tggcctcc   4320 ccgtctgcat gacgacaagg aggaattctg tggactcatg atgccaagat ca #tgtatttc   4380 tgatgtgtgt gtcagtgatg cctttcacta tacgttaata tgttagcatt ct #ggtgtctg   4440 cctcaggcat gtgtattttg gttacttcaa gtctcttagg gcctgatagt cc #ttggggac   4500 acagaactac aataactaag ccacagggac aaagagcggc aataattaag cc #acgtcttg   4560 ctctccacca gagctctact acctcctaat ggttgtacat tcttctgact tc #actagtag   4620 tgtgaacaaa tattgtaata caataaaaac cagtgtgcat gtgatcgtgc ca #aatcactt   4680 ctcaatatat ctttgatttt tttttttaat ttattttttt agagacgggg ac #tttttgtg   4740 ttggccaggt tggtcttgaa ctcttggact caagccattc ccccctcccc cc #caccccgc   4800 ttgaggattg gcacacggcc atgtatttga ttcttaccca gcactttctc tt #tagctgag   4860 cgtggtggct cacgcctgta atcccaacag tttgggaggc cgaggcagga ga #atcccttt   4920 agctcaggag ttcgagacca gcctgggcca cttagtgaga cctcctgata cg #gtttggct   4980 ctgtatgccc acccacatct atctcgaact gtaatcccca attacatttg gg #gaccaggg   5040 agggtcaagg gagggaccag gtggaggtaa ttggatcatg ggggtggatt cc #cccatgct   5100 gttctcatga tagggagttc tcacaagatc tgctggtttt ataagtgttt gg #tagttcct   5160 cctgtgttca ttctgtctcc tgccgccttg tgaagaaggt gcttgtttct cc #ttctcctt   5220 cttccaccat gattctaagt ttctgaggcc tccccagcca ttcagaactg tg #agtcaatt   5280 aaacctcttt cctataatta taaattgccc agtcatgggt aatttcttta ta #gcagtgtg   5340 agaatggacc aatacagata attggtacca aagtagttgg cattgatata ag #atacctga   5400 gaatgtggaa attactttgg aactgggtaa caagcagagg ttggaatagt tt #ggagggct   5460 cagaagaaca aaggaagatg taggaaagtt tggaaattcc tagagtcttg tt #gaatggct   5520 ttgaccaaaa tgctgaaagt gatatggatg atgaagtcca ggctgaggtg gt #ctcagatg   5580 gagatgagga gcttcctggg aactgggcaa aggtcactct tgctatgctt ta #gcaaagag   5640 actggtggca ttttgcccca ccctagagat ctgtggaact ttgagcctga ga #gagatgat   5700 ctgaaattgg aacttaaatt taaaggggaa gcagagcata aacgtttgga aa #atttgcag   5760 cctgaagatg tgatagaaaa gaattttctg gggaggaatt caagctggct gc #agacattt   5820 gcataagtaa caaggagccg aatgttaata gccaagagaa tggggaaaat gt #ctccagag   5880 catgtcagag accttctctg cagcccctcc catcacaggc caggaggcct ag #gagggaaa   5940 aatggattca tgggctgggc ccagggccct gctgctctgt gcaagagcag cc #ttgggact   6000 tggtgccctg cttcccagcc gtagctaaaa ggggccaagg tacagcttgg gc #cattgctt   6060 cagagggtat aagccccaag ccttggtggc ttccatgtgc tgctgagcct gc #aaggtgca   6120 cagaagacaa caatttggga acttctgcct agatttcaga ggatgtatgg aa #atgcctca   6180 atgcccaggc agaagtctgc tgaagggggg agaaccctca tggagaacct ct #gttaggac   6240 agtgcagaaa ggaaatgtgg ggttgcagcc cccacacgga gtccctgctg gg #gcactgcc   6300 taatggagct gtgaaaggag ggccaccgtg ctctagaccc cagaatggta gg #tccaccaa   6360 cagcttccac cgtgcacctg gaaaagctgc aggcactcaa tgccagccca tg #agaatagc   6420 agtgggggtt gaaccctgca aagccacaga ggcagagcca cccaagttct tg #ggagccca   6480 ccctttgcat cagtgtgacc tagatgtgag acatggagtc aaagatcatt tt #ggagcttt   6540 aagtaatgac tgccctgctg ggtttggact tgcatgaggc ctgtaagccc ct #tcgttttg   6600 gccaatttct accatttgga atgggaacat ttaaccaatg cctgtacccc ca #ttgtatct   6660 tggatgtaac taacttgttt ttgattttac aggttcatag gcggaaggga ct #tgacttgt   6720 ctcaggtaag actttggact tggacttttg agttaatgct agaatgagtt aa #gacttttg   6780 aggactgttc ggaaggaatg attggttttg aaaaatgagg atatgagatt tg #ggaggagc   6840 aaggggcaga acgatatggt tggttctgtg tctctaccca aatctcatct ca #aattttaa   6900 tccccatgtg tcaaaggagg gcctatgtgg aggtaattgg atcctggggg ca #gattcccc   6960 catgctgttc ttgttatagc gaattcttat gagatctgat ggttttataa gt #gattggta   7020 gttccttctg tgttcattct ccttcctgct gcctagtgaa gaaggtgcct tg #ctttccct   7080 tttccttctg ccatgattgt aagtttcttg aggcctccct agccgtttgg aa #ctgtgagt   7140 cagttacacc tctttctttt ataaattacc cagtcttggg tatttcttta ta #gcaatgtg   7200 aaaacgtact aatacacctc gtttctaaaa atcagctacg cattgtggca tg #ttcctgta   7260 gtcccagcta ctcagtaggc tgaggtggga agatagcttg agcccaggag at #tgaggctg   7320 cagtgagcta tgattgcacc actgcactcc agcctggaaa aataaaataa aa #gtaaattc   7380 atgagaggca aggttgactt tcagagagtg tgtgagggaa aggtaagaaa ca #aaatcgga   7440 attagaaaat gactgttgcc cctctctttt cattcttcac tgcttttctg ag #cacctctc   7500 acctcccttt gaaaaactgc tctaaagtac ttttaaagca gaaaatagta gc #ttgattga   7560 atagatactg tattaaatgt atattgtgta ccaggctctg agctaagagc tt #tacatctg   7620 ctctctaaat taatctccac ctctctccat gagtaggtat tatcagaaag ac #atcacaag   7680 gtaacacaaa tgttgagatt tgaaccgaga tctgtcttcc aaagtccatg ct #actaataa   7740 ttgttaggcc acttggtggt aaaaagcgtc ccctgtatta attagctgtg ta #attttaat   7800 ccttcaaccc agattagggg tctataactg aataaccaaa aagttattca gt #tagaatag   7860 ttcagttagt tattaactaa tcatagttat ttggtcaagc gcagtgactc ac #gtctgtaa   7920 ttccagcact tggggaggct gtggcaggag gatttctaat aatagtaact at #tactagag   7980 acctgataat aattattaag tctcttactg aagaagtttt actcttccat ta #agatgccc   8040 ttatttataa gtattataat aaaatactga actcatatga attaattacc ca #tgtagact   8100 gaaagacata ggttgtcata taatggttgt catataaagc atgaaggagg at #tgtcactt   8160 tgttttcttg ttgcactgta attgcctggg atatcatgaa agttcttact gg #tttaatga   8220 atatgtaatg ctgtggggga aagaatgaaa ctcaggccaa ctactttgac tg #gtgtctgg   8280 caaagtcaac tttcattgcc attttaatat ggcgccgggc gcggtggctc ac #gcctgtaa   8340 tcccagcact ttgggaggcc aaggcgggcg gatcatgagg tcaggagatc ga #gaccatcc   8400 tggctaacac ggtgaaaccc catctctact aaaaatacaa aaaattagcc ag #gcgaggtg   8460 gtgggcgcct gtagtcccag ctactcagga ggctgagaca ggagaatggc gt #gaaccctg   8520 gggggcggag cctgcagtga gccgagatag cgccactgca ctccagcctg ga #cgacagaa   8580 cgagactccg tctcacaaaa aaaaaaaaaa aaaaatatgg ctagagcaat ac #atgttcat   8640 tagagaagaa tcagaaaata tctaccaaaa gaaggaataa aacaaaacac cc #ccacaatc   8700 cgattcattc cagaataact acttttaaca ccctggtttg tgtgctttca aa #ctctgttc   8760 tcccatttcc aaaggatgtt gaggaacacg aacttaaaat agacagtgtt tg #tataaata   8820 taaattcctt ccttgctatt gaaatctttt ttcctctgac caatcttagt ta #aatggaag   8880 gaaattgttt taaaactaat tttcaggtct ggaaagatag atatgaatat gg #aaatgact   8940 ttctttgggg gaagggatgg actgaagatg gttattattt tctccttttt tc #ttatttat   9000 gttttctgca atgacaagta ttttgtaata acaaaaggaa actttaaaat ta #ttcttcct   9060 ctaaagtttg caatctacct gtaaatgggt gattagaaga taaagattat aa #ttatgggg   9120 gttttatcat ccaatgttac agtttttcag gaatattctt acaagtttct tg #acattttt   9180 attttataga taccctatat taatcttgtg aagcatttaa catctgcctg tc #caaatgta   9240 tgtcgtatat cacggtaagt ttacagtcca tactgcaact actaaaatta tc #cattttta   9300 aatttattat tgtttaaaaa attttttttg tagcgatggg gagctcactg tg #ttgcccag   9360 gctggtcttg aactgctggc ctcaagctat cctcccaccc tcaggttccc aa #agtgctgg   9420 gattgcagac ataagcaccc ggcctaaaat tattaattat attgcctgta aa #tttctatt   9480 ctaaattgta gatctctgcc tattcaaaaa acaggaatat aataaagttt ga #gctcaacc   9540 cagagcacaa tgaacatagt ttagtttttc tttgattttg tgggttctca ag #gccctatt   9600 tataaaagtg atctattgat ctgtcattta gcaagaatag aattctgtat gt #ttttccaa   9660 attataatga ccttttcaga ttcatgatta atttctagca aatatttggg ct #gaattttc   9720 cgtatctgag tctactaaat atatatgtat ataaaactta cttgaaaatg aa #gtcatgtg   9780 catttttgca tgtcccaggt ttcatcacac aaccccagac agtaaaacac ac #agtggtga   9840 aaaatacacc gatcctttca aactcggttg gagagacttg aaaggtctgt at #gaggacat   9900 tagaaaggtg agttttttat tctgctgtga tgtaatgttt tagcttacca aa #acttacta   9960 aaattttatt ttatttttta ttcttataat tattattatt ttttgagctg ga #gtctcact  10020 ctgttgccca ggcttgagtg cagcggtgca atctaagctc actgcaaccc tt #gcctccca  10080 ggttcatgca attctcctgc ctcagcctcc tgagtagctg agattatagg ca #tgcgccat  10140 cacacctggg taatttttgt atttttagtg aagacggggt tttgctatgt tg #gccaggct  10200 ggtcttgaac tcctgacctc aggtgaccta cccgccttgg cctcccaaag tg #ctgggatt  10260 acaaaaaaac agtgcaggtt ttcagatctg tacaatgcag tttgcaatct tg #attcacgt  10320 atggtcaagt ttcaaatgtt tcttgagaag aatacatatg acccagtgcc ag #gcaatatg  10380 aagaatgcaa tatgtattta tgtccagaaa gaggttatgg cagggttggg aa #cctgaagg  10440 aaaaaaatgg tccaggtagc tcatgcttgt ccaatgagtt atcccacctt tc #ctcttaaa  10500 acccaccacc tcccagtgac tccagctgtc tcttccttat ctaattctga at #gtcattgc  10560 cagtgtgccc caaatatggc tttcttcatt caactctttt tcctgaaaac tt #tcagtagt  10620 tcccaacctc acgtggttgg gcaccgtggc tcgtgcctgt aatcccacca at #ttaggagg  10680 ccaaagcaag aggactgctt aagcccagga gtttgaggct gcagtgagcc at #gatcccgc  10740 cattgcactc cagcctgagt gagagagcaa gacatttttt ctgtctttag aa #aaaaattg  10800 gctgggcacg gtggatcaca cctataatcc tagcactttg agaggacacc ac #ttcctgtt  10860 tcacagacag taggggctgt ggaggaagaa ctccttcagc tcctgctctg tc #gcaattgg  10920 ccagcttgcc tgcgccttct ctggcgattg cctgctctcc tcccacccgt gg #aagtcatg  10980 tcccttccct ctctaggggc agtcccttag ccaacctccc tagtttctta gg #aactcccc  11040 cagacatggc ctctccctct gtctgcaaac tttcattggc atggtcttcc at #atccattg  11100 ggtgttcagt ttcttcacct gcatttttaa aaggcccatc cactgaccca gt #gcttcact  11160 ccctcccttc cctcacagta tcccctgccc tctgccttcc tccagtgcct tc #atgttccc  11220 tccactattg cactggggcc ccctttccag cctctcctct gaagctggtt tt #gcttgggt  11280 cactgatagc ttccctgtgc taaatccaat ggatgtgtta ccagcagcaa at #ttgtacag  11340 gtctgcagca acctcaattc ttgcctcctc agaagaaaga attcgactga gg #ggcctaag  11400 gcagaaggag agacggaggc aagttttaga gcaggagaga aagtttatta tt #aagtgtag  11460 agtaggaagg gaaggaagta aagtacactt gtaagagggc caagctggtg ac #ctgagaga  11520 aagtgtggtt tgaccttgga atttgggttt tagatgttgg catacttcca gg #gacttgca  11580 tcccatctcc ccggtttctt cccttggggt gggctgcccg catgcgcagt gg #cccgccag  11640 tgttggggag gggagcatgc tcagtgtgtt taccggagtt ttgcgcatgc tc #acgtgagg  11700 cattcttccc ataccagtcc cagttttcct agaaggacat acaccaatta ag #ctctgcca  11760 ttttgcctct tagtgtgcat ggttgagccg actcacccaa ctcccgagat ct #tattggga  11820 agctgatcac cagtttcagg tttttgtatc tattgagaga ctgccgtccc tt #ggcaccag  11880 ctgtgaccaa ttagtatttt agcgacacag ttaacaactg cttgaccatc ac #gtgatggt  11940 cgccttcctg ttgtgggtcg gggagccctc tcctgccctg ctcatgcctg ac #tagctatc  12000 tactgtaacg gacacttcct ggttttctga ccattgggca ctattgactg ta #acccctcc  12060 ttgaaacatg gttcccttca ctctgcactt tgttccccct ccttatcctg ag #gcttttct  12120 tcggttcatc acctccagct cacttccttt aattttgcca ttccctgggg tt #ccgtgggc  12180 cccctcctct ctctcttcct tatatatctg tgtccatact tacgtctctc aa #ataatatc  12240 actactccag gttgaatcac atctcccaca cccaggtagc taactactca cc #gggaacgc  12300 catggggcgg ccatgacggt ctcaggctta actcagctga gactctactt tt #cccccacg  12360 agttgtttgt tctgctgttt tcctgttcct tgggaacctg ggaagaaccc ag #gacttgtc  12420 cctctccttc ccctctatgt ccttctagtc tgcctcttgt cagtccccac tg #ccccaggc  12480 caggcaattc catgcccctg gtcctttcat tcgtgctctt ctcctccctg tc #tcagcttc  12540 cgaggtgaca gcttacctgg gtgacagcac cacacccatc acactgtgtt gt #gtcaacgg  12600 cagtgatcgt tttacttctc cccatctaga ccctgagctc cttgtaggca ag #gcttgtct  12660 tactttacct ttgtgacctc tgtgtctgtt acagtgcctg gcactaagtc gg #taatttac  12720 tgaatgaacg atgggcccac tttgttgtgt tcacctgtgc cgagctgagg tt #cattgact  12780 cccactgcat ccaggggata aactctgact tagtcttgga gtggcagata ca #agcgacac  12840 acacccgtca gctggaaggc tcttgtcctc tttgtgaatc agaaccctgt tt #aggcttct  12900 aatcccacat caaagcccat ctcctccatg aaatactcag tttttctagc ct #gcactgat  12960 ctcttccttc cctgaacttt caatgtattt aatgtacagc attgttcacg ct #accactgt  13020 attcgtcatt gattgtttca tatttgcaaa atgtttctct ccccagttca gt #tgtaggct  13080 ccttgtaatc cggcagccca tgccttatat gggctctatg cgcttacgtg gg #cctctatg  13140 aaccctcaaa atgtcttttg ccaaataaag gccaagccag atggactgag cc #ctgtttct  13200 tctccttggc tgtggcctta ctatcttcct gcccctcgta aacagctttg cc #cctgggag  13260 tttgaggctg cagtgagtta tgatcgtgcc actgccctga ggcctgggtg ac #agagcaag  13320 accttgtctc taaaaaaatt aaaataaaaa atttaaaaaa acaactttgc ca #ccctaccc  13380 atcacacccc acccgcctga cctgcttcac aggctcccga cggccactgg ct #tccacctt  13440 ccccatcttt ctcttcccgc ctccatcttt taagctgcga accagcccct gt #tcctttca  13500 ctgtccagct gtcaatgagc ccagagtccc ttagccacct agtgctttct tc #cccctcct  13560 gctgtctctt ggggtcttct ggtgtctgat tctgtcagcg gggcaggtgg ca #gtacctgt  13620 tctagcattc aggccacttg gggctgatcc acgcattgtt tatgttctag cc #tgcaggac  13680 agccaggtgg atggccctgc agcgtgggag ccttgcccac ggagtgttga at #ttcttaat  13740 tgaaatgaat acacttaaat taaaccaaag ttttgtagaa gaaatcctgg cc #aggcacgg  13800 tggctcacgc ctgtaatccc aacactttgg gaggccgagg cgggtggatc ac #ctgatgtc  13860 aggagtttaa gaccagcctg gccaacgtgg tgaaatcccg tctctactaa aa #atacaaaa  13920 aattagccag gcattgtggt gggtgcttgt aatcccagct gcttgcgggg ct #gaggcagg  13980 agaatcgcat gaacccggga ggcggaggtt acaatgagct gagatcgttc ca #ttgcactc  14040 cagtctgggc aacaagagcg aaactccgtc tcaaaaaaaa aaagaaatcc tg #ttggcttt  14100 ctgtgcagtt ttttgatgcc attgtgacac agagaaactt tatttcagga ac #tgcttata  14160 tcaacatcag aacttaagga aatgtctgag tactactttg atgggaaagg ga #aagccttt  14220 cgaccaatta ttgtggcgct aatggcccga gcatgcaata ttcatcataa ca #actcccgg  14280 tgagctcttt ttttcattcc tttcttgttt ttatatttgg caagtctttc tt #cccggggt  14340 tacttactgt ttcatttccc atttaagaat tagcatatac cggctgggca tg #gtggctca  14400 tgcctataat cccagcattc tgggagcctg aggcgggtgg atcgtgagat ca #ggagtttg  14460 agaccagcct ggccaacatg gtgagacccc gtctctacta aaaatacaaa aa #aaattagc  14520 cgggcgtggt ggcaggtgcc tgtaatccca gctacttggg aggctgaggc ag #gagaatcg  14580 tttgaatctg ggaggcggag gttgcagtga gccgagatca cgccattgca tt #ccatcctg  14640 ggaacagagc aagactccgt ctcaaaaaaa ccaaacaaaa caaaaaacat gg #gggatttt  14700 taaaacaaaa ctttggaggg gattttaata aacgatagaa ggtatatctt aa #gaaacaga  14760 gcacgaggga gaaactacta cttactgatt tttatatttt cctttattaa gc #ttttcagt  14820 tgtcccatta aatgttccct actagattac ggggagttct taacttgagg tt #cacgggag  14880 ttgtgggatg tctgtaaaca acttgacatt gtatgcaaaa ttttgtgtat at #ttggattt  14940 tttggggaag gatttctatg gcttacagtt tattctcaaa gggaagtagg gc #cctaaaag  15000 ctcaggaccc cgtgtttgtt ttctctctga atcttgctaa ccatggtgtc tg #ggtagaga  15060 aagtaggaat ccacacaaca gtagactcag acttgacatg tccagaacac ag #agttgtgg  15120 tggatcctga gacttgcccc cagatccccc gtcagtgcac gactctgccc ca #gctgctgt  15180 atcaggtatg gttggtacct gttggccttc atttcttagc ctcttcaagg at #tgccttgg  15240 ctacaaagag tcctctcacc ttaggctgtg ccccttcggg aggcagccca ca #tccaggga  15300 ctgatagatg aagggccatt ctacctgcac accctagagg gtgtttcagg ct #gttgattc  15360 cagctcagct tctcctgcta cccagtcctg tatcctctcc ccctccctca gg #tgtcagta  15420 atcccaaggg ataatcccga ataaacatcc tgtcctttaa acttcatctc ag #agtctgcc  15480 tcctgcagaa cctaacttgc aacagagctc agcaaaaccc aagctcattt ta #ttaaagaa  15540 cccagatcaa aaaagagctt tatgggctgg gcacagtggc tcacgcctgt aa #tcccagca  15600 ctttgggagg ccaaggtggg tggatcacat gagttcagga gtttgaggct ag #cctggcca  15660 acatggtgaa accccatctc tacaaaaaat ataaaaatta gccagtcgtg gt #gacacaca  15720 cctataaatc ccagctactc aggaggctgg ggcaggagaa tcgcttgaac cc #aggaggtg  15780 gaggctgcag tgagcagaga ttgcgccact gcactccagc ctaggggaga ct #ctgtctca  15840 aaaaaaaaaa aaaagaaaag aaaaagagct ttatgataga tttctataaa at #tgcttcac  15900 tcactgaatg cagcacagtt atagtgtctg catgtttctc agacaagcca aa #cctaccta  15960 gcctgctcag ctgcctcatt gaagacactg ttatcactgg cacctggatc tt #ggcaccat  16020 ccattcctgt gtgaaactct tttagttcta agaagtgaat atcattgcca gc #aatcagga  16080 taacagacta cccaaattgt gctgtacaga gatctgttga tatcaatttt gc #aaatagcc  16140 aatggcattg gattacatta gtccagtttt caaagctgaa ctagatgttt ag #ggggtcaa  16200 attattagac acagttttca cagtagataa caggttgaga gtccaggtgt ga #taacaatc  16260 ctgtattcag aggaggtaac ttttatagca ctataaaaaa ctaaggaaat ta #ccaaagcc  16320 tatccctgaa aagactgtaa caaaacagcc atttagcact gactggctcc ag #tgattcca  16380 aaggtcaggc cactaacaac tgtagagcca ttcctggttt ctgtgtgttc tg #tgtcactg  16440 agccagccac tgctgctgct gtttatggga taggcaagaa ggttgctacc aa #aggaaatg  16500 gttttgtctt tcacctagga gatggttctg tggatatgtc catagtcact gt #taaaacgg  16560 atctttgaag tacattctac agtaagggac acccattaag ctggagattt tg #atgagcag  16620 atggtcatca tttcatgcat gagtgcaagg tcaagcataa gaacctcagt ga #gagcaaga  16680 gggctgcagg gcttgtgacc gtggtgtgtg caccttgttc agcaccctcc at #gccaggat  16740 gaggctgatt ctgtctgcaa aggaatcaac tcctatactt tttttttttt tt #ttgtcttg  16800 ctctgtcacc caggctggag tgcagtggca caatctcagc tcatttcaac ct #ctgcctcc  16860 caggttcaag cgattcttct gcctcagcct cccaagtagc tgggattaca gg #cacacacc  16920 atcacgccca gctaatgttt gtatttttag tagagacggg gtttcatcat gt #tggccagg  16980 ctagtcttaa actcctgacc tcaagtgatc cgcctgtctc cccctcccaa ag #tgctgaga  17040 ttaaaggcat gagccaccgc gcctgggcac tcctacactt tccttaccca tc #cccaattt  17100 gaaagaactg aatgctggtt agtccatagt accctggacc ctatagagaa ag #ctctgcac  17160 agagcaacct ggataagttg tagatccagg tatcatcata ggggtctctc tc #cacatatc  17220 ccaagattca gaagctcttg taatttcttc ttcagtggca agcaaataag ca #atagtgtg  17280 aaccctgcat catttatgat gcaactttgc agacatccat tatatccaca gc #taaatctg  17340 aaaatattca ggggttgctg cttttagata ccaattattt tctcttgaca tt #aaaatgct  17400 aacaaatcta tgactgttag gatcaagtta aaaaaattcc cactgaagag ag #acagactt  17460 tattctgagc cttacgtgtt tctttaggtt tagaaggtga atgagcagtg gc #tggggagg  17520 atggcctaga agttggagct cacaggcttc ctccctgcac tctgccattc ct #tagattgg  17580 aggcgccctt gatacagatc cctccctaca cactgggggt ttacttgcaa tt #taagactt  17640 cacattttat attagtatga acagggaaaa tatattttgt aaaaccacat gt #aaacctcg  17700 taaaggattc actggtaggg tcattatatt attctgtcta tttttaggta tg #tttgaaac  17760 tcttcattat taaaaaaatt tttttggccg ggtgcggtgg ctcacgtaat ct #cagcactc  17820 tgggaggcca aggcaggtgg atcatgtgag gtcatgagtt tgagaccagc ct #tgccaaca  17880 tggcaaaacc ccatctctac taaaaataca aaaattatct gggcgtggtg gc #acatgcct  17940 gtagtctcag ctacctggga ggctcaggca gaagaatcac taaaacaagg ag #gcgaaggt  18000 tgcagtgagt caagattgcg cccctgcact ctagcctggg tgaaagagca ag #actccatc  18060 tcaaaaaaaa aaaagataat tttttaaatc taatgaagga ggaaagaaaa gt #cctgacag  18120 gcatgctgaa tcatagcata ctcttgcagg tgtgaagtac agaggacgta gc #caactctc  18180 aagaccaagg gcttcatttt ccatgctacc ttgcctgtca cctctcccag at #cctgggaa  18240 aatgtgatcc actatttcac agtaggaaat agaaatggtg cccagttttt tg #aaggcttg  18300 attcagtttg gcattttgga gatgtcatct taaggacagt gtgaggtttt tc #tgtaatct  18360 gtgcattttg gtcatctgtc ccaccctcat gttatggata agcagtggca gc #atttccca  18420 gatgtaagct gacacacact aaagctgaac tggataaaaa atacatcagg ta #aaactatg  18480 gaacatctga aatatgatgt atattctacg tagaagctgt gttacagtac ca #aataacat  18540 ttcagtttca tcctgatttc atcagtcaac aatttagcca tgcaaaatga ca #ttttttat  18600 tctatttatt tatttattcg gagacagagt ctcgctctac cccccaggct gg #agtacagt  18660 ggtgcaagtc tcagctcact gcaacctcca cctcccaggt tcaagcgatt ct #cctgcctc  18720 agcctcccaa gtagctggga ttacaggcac ccactaccat gcctggctag tt #tttgtatt  18780 tttagtggag acgtggtttc gtcatgttgg ccaggctggt ctcgaactcc tg #acctcagg  18840 tgatcctcct gcctcggcgt cccaaagcgc tgggattatg ggcatgagcc ac #tgcgccag  18900 gcgcaaaatg acatttttag atggatatat agtctatgaa atttcaaaat at #tttaagaa  18960 atctttgttg taataatagc ttcagattac caaaacaact ctagtatctt gg #tgagtgct  19020 gccaatttca ttgcaacttc tcagcaggag ccccgtctgc tgatgtaatt ta #tcataatg  19080 gaagtggtgc ccaacttctg aatgcatgag aaaggctaga ccttacctgt tg #ttttaagg  19140 taaggtctac tgctaactag taggaggtgt ctaatttatt agactgaaat tc #acttgcaa  19200 aaatattcta aaagccttat attaaaaaaa aactgtaaaa gtttatatct tt #tcctgtgc  19260 attcaactca aagaagatag ggcctagtaa atttacctga aaaatattta ag #tattctaa  19320 tataaaaact gaatctcact gagggattca ggtggcttaa aactcacctg aa #ccctgaac  19380 ctctattttc tcatttactg aagtttattg gggtttttgt ttttttgtgt gt #ttttttga  19440 aatgaagtct ctgtcaccca ggctggagtg cagtggcata atctcggctc ac #tgcaacct  19500 ccacttcccg gctcaagtga ttctcctgca tcagcctctc aagtagctgg ga #ttacagat  19560 gcacaccacc atgcccgact aatctttgta ttttaagtag agttggagtt tc #accctgtt  19620 gtccaggctg gtctcgaact cctgacctca agtgatccgc ccgcctcagc ct #tccagagt  19680 gctgggatta caggcaggaa cctgtaactg tgcctagact acagaagtgg tt #tttatatg  19740 ctaatttgtc cctaccctcc actgcttttg ttttaatact ccccccttag aa #gaatttgt  19800 tgtgatctag acatattaag aagttgtaac tgaaatatta ataaagaatg ag #gccaggcg  19860 tggtggctca cacctgtaat cccagcactt tgggaagctg aggtgggtgg at #cacctgaa  19920 gtcaggaatt caagaccagc ctggtcaaca tggtgaaacc ccatctctac ta #aaaataca  19980 aacattagct ggatgtggtg gtgtgcacat gtaatccaag ctacttggga gg #ctaaggca  20040 ggagaatggc ttgaacccgg gaggcagagg ttgtagtgag ccgagatcac ac #cattgcac  20100 tccagcctgg gcaataagag tgaaattcca tctcaaaaaa aaaaaaaaaa aa #aaggaatg  20160 agtagcactg tagacatgat ttccaggctg agagcagttg aaagggtcta gg #gtttagtt  20220 ctaaggctgc tggtaagagg agccagcgtg acatcatatt ttaaaattat at #gtaaagca  20280 agatcaaaag ctttcctcat gctgatttag tgtcgatagt taaattacag ca #ccttttat  20340 gtagttatac ttcatttttc attgctttct gccgggtctg aggaattgga at #gagcatta  20400 ccttgtgcag atgttcagat tcgattttta aagaaaaagt catatttcag aa #tccctctc  20460 ccttttttcc cctctaagat acaacctgat ggtatttgaa aataagcatt tg #gaataagt  20520 gcaacatttg gttagtgtgt gtttaaatga ggatatgttt taggttccaa at #ggttattt  20580 cgccagtttg attttcttga aatttagttt ttaaaaattg ccatagatga tg #gtggtaat  20640 aatgattaaa atgaaatggg ggacattccc tctgaactgt aaaatttata tc #tgtgtcct  20700 gtcttcttga gcctacttat cctatagttt gtgttaaact tgggaaataa aa #gtttaaat  20760 ttctaatgag aaggttaaat gtgagttgga agaaagtttt acaaacatct tc #tgttggtt  20820 actgaggttg tcatactaaa cgtttaattt aagacattac tacgcggggt gc #ggtggctt  20880 acgcctgtaa tccacacttt gggaggccaa ggcaggcgga tcacttgagg tc #aggagttc  20940 gagaccaacc tagccaacat ggtgaaaccc catctctact aaaaatataa aa #tttagctg  21000 ggtgtggtgg tgtatgcctg tagtcccagc tactcatgga ggctgaagtg gg #agaatcac  21060 ttgaacctgg gaggcgaagg ttgtgagcca atattgcacc actgcactcc ag #cctgggtg  21120 acagagcgag accctgtctc aaaaacaaga aaagacagta ttaaaagcct tg #aacattga  21180 gacagttgag tctttaaaat acttttaaaa aatgcttctc acctatcttc cc #tatccacc  21240 ccaaaattta attgtaaact tataaactta aacacctgac caagaacact gt #tataaaga  21300 tgattcttca gcccaataag atcagccaga cttctgatcg tttactgttt tt #ttggctaa  21360 tggtacaatt tctacttctt caatggggaa ttcataaaat gtagttgtgg ca #gggtttct  21420 catacatttg taaatgtata gaaatggctg tgtggtgaag ccagagtttt ta #taccgttt  21480 ctcttagaga aataacattc tttatcctag atccgatgtc cagttttcac aa #gctgattg  21540 ctgagaaggt tctaggcggc gtctgttaaa aagcattgct ttctgttaat ta #gacatgtg  21600 caagccagcc agcgcgccat agccttaatt gcagaaatga tccacactgc ta #gtctggtt  21660 cacgatgacg ttattgacga tgcaagttct cgaagaggaa aacacacagt ta #ataagatc  21720 tggggtgaaa agaaggtatg gttttttggt ttttttaaaa tctctcttac tg #aatcacac  21780 gcttttcgga ccgcatttgt ttctcagatt tgtctcatta aaaatatgct tg #ctcaaatg  21840 taatgtggtc ttctgaattt caaaaaagta ttcatgtctt gtccaaatac ag #atatttga  21900 taaataaata ataaaaaata ccatggaaaa ataaacttag tatttctaat ag #aattcctt  21960 tggttataag gaaagggatt ttcatgggtg tccaaaaaat gtatttcatg ag #gaatcata  22020 cgttttactt ttgggcttag attacccaga ttcagtttaa ttttttaaac at #ttgtataa  22080 ttgagtgctg catataaatg ccaaagcaaa caaataaaac taataaaaga aa #aaagaaac  22140 ctcagagaga tactgttctg ccatgaaaat tctgtctttt gaaatagaag tt #ctgtaatt  22200 gggtttggtt catatatgta tatattaaag catatttcta tattattagc at #tgggaata  22260 tgggaaacag ggacttggtt tgaggatgca tagatcctgg gttgaaggat ga #gaataaag  22320 ttgaacagat gagaatgaaa atgcacaggc atccatcgcc atcaccacac ac #gtgctcta  22380 caaacaaaaa gtttgtgcag gccaggcgca gtggctcatg cctgtaatcc ca #gcactttg  22440 ggaggctgag gtgggtggat cacctgaggt caggagttcg agaccagcct gg #ccaacaag  22500 gcaaaaccct gtcactacta aaaaaacaca aaaattagcc agtgtacacc tg #taatctca  22560 gctactcagg aggcttaggc aggagaatcg cttgaacctg ggagagggag gt #tgcagtga  22620 gccaatatca cactactgca ctccagcctg ggcaacagag tgagactcca tt #tcaaaaaa  22680 aaaaaaaaag tttgtgcaaa caactacccc accctcacct ccttttctct ca #tagattta  22740 tagtattcct ggttcattcc tatttaattc tccttattaa aagaagagat at #atgtatat  22800 acacacacac acacacacac acacacacac acacatacat atatatatgt tt #attgttat  22860 cttcacatgc tggttttatt tgaacataaa tgactgtttt gaaatcgagt ct #tgcaattt  22920 catttatatg ccttttattt caaattttag attaaaaggt tttacgtcct gt #tgactaaa  22980 ttctgtacat cagaatgttg gccaaaaagc agatggcgtt tagatttgga ga #ggatgtgg  23040 gtaactctat gacccatccc tgccgtcagc tgtatctgtt ttcaggcata gc #cagtccta  23100 aagccttatg tggagccttg ggcgggggaa gaggatcaag agaacaaatg at #ggtctccg  23160 ccttggctag cccctgtgtg tctgcctctg ccactgggga cctctttctg ag #ggcaggtc  23220 aaggacacat gtgccgcctt cacctgcctc tttcagttct gacagccatc tg #cttagcac  23280 agggctactt gccagttcct acctgtttct gcctctgacc cacaactgct at #gttaccgg  23340 tacaaaaccc cccacacaca gtgccccctc ggtgagccct tgttaggcct gg #cctgggct  23400 tcctagcact tctttccttt aactcccacc cctggccgtc acagtcctgt gg #cttccatg  23460 tcatatgctg gacctttggt ctctaggatc tccccggcca ggtgaagaag ga #actaaagg  23520 ccaaaggatc ccgagccttg agctgctaat gatgtagggg ctgggtcagg ga #atgtaagt  23580 gggtacctat atatcataat ttgtaaaatg actttatagg catatactta ca #tcaggatg  23640 tcttacataa tatgtatatt atataaagtg gtgattaatt ggtaaacaca at #gaacatca  23700 ctgtttagat actgaagaac ctaagacaat aagtacctaa atagttatgt tg #aaaattct  23760 gtgaactcta gcctttataa ctaattacta cagaatgtaa cacttacggc cg #ggtgtggt  23820 ggctcacgcc tgtaatccta gcactttggg aggccgaggc agttggatca ct #tggggcca  23880 ggagttcgag accagcctgg ccaacatggt gaaaccccat ctctagtaaa aa #tacaaaaa  23940 tacctgggcg tggtggtgta cgcttgtagt cccagctact catgaggctg ag #gtgggggg  24000 attgcttgaa cccaggagga agagtctgca gtgagccgag gtcatgccac tg #tactcaag  24060 cctgggcaac agagcaagac tctttctcaa aaaaaaaaaa aagaatgtaa ta #tatatctt  24120 taaatatgca aattaatgtg atatataggg tgtatttggt tatagcatat aa #ttcaacta  24180 tttatgcagt agtttataac tagttgctaa tacagtgtag acatccatca ca #gtctaaag  24240 aagactggaa atatgttgat tgcttagtgt tcaatggaaa aacttttttt tt #tttttgtc  24300 taggaatgag gggcagtgcc acatagtaca aaaagcattt cacttggagc ca #aaattctt  24360 tggtttaatt tttattgaaa ataacatgta tcgtgccatg ctctggggtg tg #ctcagtac  24420 tagctgagat gattcctagt ctgagctccc actccactcc accctcccca ct #gccctggg  24480 agcatagaga ctagagcatc actgactggt acgcaaggtg tgatggtcgc ag #catgcatg  24540 ggtgttgtac acgcacaaaa gggaggcatc tgaccagact gagggatcgg gg #ggaacttc  24600 ttagaggtgg catctgaacc aattatgcaa ataagtccac tcagtgaaga ag #ggggcaga  24660 actttttgag cagaaggaac agtaagtgga aaggcacaaa ggaagaatga ac #atccagtg  24720 tagtgaaact gaaggcagct gcattttggt ggggctggtg agtgaagctg ct #ctccctct  24780 ccaggcattg atttcttcag gtgtcaactg gggagatgga catggtcatc tc #tgagagcc  24840 aatacagttc aagtactgtc ccaaatctgt aaccgattat tagaaactgg ga #agagtgac  24900 atggtcatct ctgagagcca gtccagttca aacactgtcc caaatctgta ac #tgattatt  24960 acgaactggg aagtgacatg gtcatctctg agagccagtc cagttcaaac ac #tgttccaa  25020 atctgtaact gattgttacg gactcctgtt gaggaagaag aaggtaaaaa ac #cctgcatc  25080 caagatgagc ccccacttcc acgaagctcc cttccagtca gtttcatcat tg #gctctact  25140 gctctgatgg atttttcaga acgttctgtt ttccccctgt ctttttctag gc #tgttcttg  25200 ctggagattt aattctttct gcagcatcta tagctctggc acgaattgga aa #tacaactg  25260 ttatatctat tttaacccaa gttattgaag atttggtgcg tggtacgttg at #tctgattt  25320 ttcttctttg ttattcaacc ctggtgttta gccaggcaat aaagccacct ct #caaatgac  25380 tcctttcctt ctttataggt gaatttcttc agctcgggtc aaaagaaaat ga #gaatgaaa  25440 gatttgcaca ctaccttgag aagacattca agaagaccgc cagcctgata gc #caacagtt  25500 gtaaagcagt atgtacgttc tgtctttctt caagttaaag cctcatagct ct #tttttggg  25560 agctaatttt cctagaaaat atttcggtga agaatcttaa aatagtaccc aa #aaatccca  25620 agaggttaat gaggaaaaga atgacatccc caaacaatag aggacttctg ct #gtgttttc  25680 atttttgcca tcttcttttg gtatgcaggc gttgactttt catcttttct tc #ccaagaat  25740 tcaatcaaaa taagctttcc cgcaccttcc ccaatctgat tgccaaactg ta #tcattttg  25800 aacaatttat cataatttct ctaatgattg atatcacaca cactctttct ga #cacttcac  25860 cttttagaaa tgaagtgctc tgttctttaa tataatattt actcaggaaa ag #atatctgt  25920 tagattgtac tagcattcta tgaacttttt tttgtttttt tgttttttgt gt #ttttttga  25980 gacagagtct tttgctgtgt ggcccaggct acaaagcagt ggtgtgatct tg #gctcacta  26040 caacctccac ctcccaggtt caggcaattc tcctgcctca gcttccctag ta #gctgggac  26100 cacaggtgtg cgccatcaca cccagctaat ttttgtattt ttcataggga tg #ggggtttg  26160 ccatgttggc tgggctggtc tcaaactcct gccctcaagt gatccaccca cc #ttggccct  26220 gcaaagtact gggattacag gcatgagcca ttgcacctgg ccaatacatt gc #acctggcc  26280 aatccttcta atatttttac atgaaatata aacaagtcct atttcttcag ag #tacaaatt  26340 gagtataagc cataactgtt tttccccttg ctttctccct ccctccgctg tg #catacaca  26400 tgtatacatt ttttttttaa tgagtaatac ctttaatccg tagacaaatg tg #tggtattc  26460 atcgttagtc caagaatgaa aagcagtctc tccatagaat tgtttatctg cc #catctcta  26520 agcctgacag atacacagag acaaaacctg gacaaatgac attcccatgt aa #ttacagcc  26580 acaaaataag gaagacctgt aagggtcgca tgtcaattgc tgtcatgata ga #ctcctaac  26640 ataattaaca ggtaaagaga gcttttgctc agacctctca gatgaaaaag tc #tcttgctg  26700 ttagtgtctc tgttttgaaa agtgtcaaga aatgtataat tgcaaggcag aa #aagaatga  26760 ggacaatctt ttcttcctaa aaagacctaa tagaaacttt aaggaatgtg aa #ttatgtag  26820 aacatgctag ccacagtctc gaccactttt gtctttttat taaaagggct at #tatgtttt  26880 tatttccaag aaattatgtg ggtttttttt ttaaagtgag atggaagaaa gt #atagacac  26940 gagatgctaa ataagagaat agcctatttt aagtgggtgc tctaacactt tt #acagtaat  27000 cctttacata ttatcatgcc cttgatggcc caactctccc tgaaggtcag ga #tccatcct  27060 cttaacacat tagggtgcct taatattact tactaatatt tatccttaag ag #gatgtgtt  27120 aagtgaggct cattgataat ttcacaattt gagactgcaa acttagaagc at #tagcatgg  27180 tcaggcaagg tggctcacac ctgtaatccc agcatttagg gagactgagg cg #gaaggttt  27240 gcttgtgacc agaagttcaa gaccaaccta ggcaacatag caagatcccc at #ctctactt  27300 aaaaataatg tttaaaaaat aaagtcttag aagcattagt agtagtgaga ct #attggaat  27360 tggaaacacc aagacttact gtctgcacca tgcagacatc ctgcaggcac gg #ggtggggc  27420 ggcaccaaat tggagctagc acagaaattc actcagtgat ggaagcttac aa #agggtcca  27480 aagaaatgga cctgagtcat gatagagagg tttccttgtg gtcactgttt tc #tgtttaag  27540 aagccaaaga taatgcacag gaattctttt ataaagatat gcacctcatt ct #tcaaagat  27600 tagcagctga acgaacagtg aacatgttaa cgtggctgga cccttaataa aa #atgaaatg  27660 tttcatgctg cccactaggg ggcatgctgg catcgtccca gcactacctc ct #tttcatgt  27720 ggtttattcc taaactccac agctcttaga ataataaagc aaaatgatag tg #tgagctat  27780 ttgaataaaa gtttctatat ttaagtgcct atgggtggaa atattccaga gg #tgttatgg  27840 attcaaaatg gctattttta cgtactcttg gtatttaaaa tgcaaagcca tg #cgagctcc  27900 aaataaatgc atgcaaagca aattagacac accaaaaaga ggggaggagg ag #aactgaaa  27960 gagcagaatt attacagaag aagaactaat gggattgcaa aatgtattga ga #attggagg  28020 gaaacttaca agctgcattc tactaaggat accatttctt catctccctt cc #ttttttta  28080 gtgaaaataa tattaaaatc taagagaggg ctgtctaggg ggattgtttt gt #gattgact  28140 gatattaaaa tagaatccat tttaggccgg gcacggtggc tcacacctgt aa #tcctaaca  28200 ctttaggagg ccgaggtgag tggatcactt tagtccagga tttcaagacc ag #cctggcca  28260 acatggcaaa accccgtctg tactaaaaat acaaaaatta gccgggcgtg gt #ggtgcacg  28320 cctgtaatgc cagctacttg ggaagctgag gcaggagaac cgcttgaacc cg #ggaggtgg  28380 aggttgcagt gagccaagat cactccactg cattccagcc tgggcaatag ag #cgagagtc  28440 tctcaaaaaa aaaaaaacaa accagaattc atgttattat caaaagatga ct #tatttatt  28500 tacatactta ctcacttgca aaatacattt tgtactcatg caaaatacat tt #tgtagctt  28560 actaataaag acagtggctt gtttcccagg aaatctggtg gaaatgagac ct #gagaggtc  28620 agagggcctg tccagttgtt gttaagccag acagtagctg agttgagact tg #aacccaga  28680 gctgggtatg gtaatcctgc cttgtttctc tctctctctc tctctttttt tt #tttttttc  28740 tgaatttcta ttttctccag ggctgcttgt ggcctggaat taatgggctc tc #ttcctatt  28800 acttgatttt caaagcctca gagtaccact acagaattgc atattgtggg tc #acattagc  28860 agaacactct tttttttttt ttttaattca tttttttgag atggagtctc gc #tctgttgc  28920 ccaggctgga gcgcagtggc atgatctcag ctcactgcaa cctccacctc cc #aggttcaa  28980 gtgattctcc cacctcagcc tcccgagtag ctgggattac aggtgcacac ca #ccacatgc  29040 cacacctggc ctcttttttt tttacaatat tcatatctat ctataggcct ca #ttcagatc  29100 ttgccagttg tgaactgtta taacgaaagg gaaaacatat ttttctgttc ca #gcatccag  29160 tccaggattt cacgttgcat tttgctgtca tgactctgta gtctcttgtc at #ctagaaca  29220 gtctttcttt gcctctcatt accttggtat ttggaagagt gcaggccagt ta #tgttgttg  29280 agcctctcag tcgggcttct ctgatacttc tcaagattcg atccaggtta tg #aatatttg  29340 gcaggaatac cacaagagcg gtgctgtcct cagctcctca taccaggagg cg #cgtgctgt  29400 cttgtctgtc ccgttactgg tgatgcatgc ctggatcgct tgattaggat ac #tgtcgggc  29460 cgggcacagt ggctcacgcc tgtaatccca gcactttgga aggccgaggt gg #gcagatta  29520 cctgaggtca agagttcaag accagcctgg ccaacatggt aaaaccccat ct #ctactaaa  29580 attataaaaa attagctggg catggtggcg ggcacctgta atctcagcac tt #tgggaggc  29640 cgaggcgggt agatcacctg aggtcaagag tttgacaagc gtggccaaca ta #gtgaaacc  29700 atgtctctac taaaaataca aaaattagcc gggcgtagtg gcaggcgcct at #aatcccag  29760 ctactctgga ggctgataca ggagaattgc ttgaatccgg gaggcggagg tt #gcagtgag  29820 ccgagattgc accattgcac tcaagcctgg gcaacaagag tgaaactcca tc #tcaaaaaa  29880 aaaagatact gtctgccagg tttcttcaat ctaaaattac tattttaacc ta #ttttgggc  29940 aaagtatttt cagattatgt aaatattatt ctgatggttg tcaaatggct gt #ttttctat  30000 tttcatcatt tcttctatat cactcttcta caagaaagtt ggtatcctat tt #tttttgtt  30060 attattattt cattctcaaa agagctgaag agttggtatt ccattgtaag ga #agctctta  30120 actgtatggg ctcttggatt cttattttat tctgtatctt tttttttttt tt #tttttttt  30180 gagccagggt atcactctgt cacccacgct ggagtgcagt ggtgcaatct ca #gctcactg  30240 caacctccac ctcccgggct caggtgatcc tcccacctca gcctcctgag ta #gctgggat  30300 tacatgcggc tgccaccata cccggatgac ttttttgtat ttttagtaga ga #cggggttt  30360 tgccattttg cccaggctgg tctcaaactc ctggcctcaa gtgatcgccc ac #ctcggcct  30420 cccaaagtgc tgggattata ggcgtgagtc accgtgccca gccatcttat tt #tattctgt  30480 agattataac actgtcatta ttttaatact caattatcca acgtatggcc ag #taggggag  30540 gccctttaac ctggctctgt gtcctccatc attttttcag caccccattt ct #ggcaggag  30600 atattcagcc ctgttattca ctgttctcca aggagcccac attccttttg gt #ggaaaatg  30660 gtgttaagaa accagaattt gagtactggg tgtcatcgtt tctagaccca ct #caatggac  30720 agagctagga aatacatgta tgtattatat gtaatgtagg tagatacgtg ta #tatctttc  30780 tgtacccatc catacttatt caaaaccacg aggtatcaaa cagatagttc ca #aatccatc  30840 taacaccaca ggatttgtgg tttattccag gattccatct ttccatattt gt #aaccccct  30900 tcccaaacag tgagagacct ggctcctctt ctccgcggtg tatttatttg ca #caatctga  30960 gaatatacca taggagttta caaattcatg actcatatct ctgtgaaaaa ca #aacccagt  31020 agctagaatt cagtatttat cattcctttt gtcttgggcc tgaggataat ag #aatcaaag  31080 cactgttcaa aagttacctt tctctacgta tcagtgtggt tgtgttatta tt #tggaatat  31140 attaacccat ttatgcctag tgttccatta ttggaatgct aagcttgtgg ag #ttatttct  31200 atcctactgc tcaaggtcat taccaaggtc tgatttttca caaaacaaat tt #gcaacctc  31260 cagcataaat gggttaatag ttggttcctt tttttttttt tttttttttt tg #agacggag  31320 tcttgctctt tcgcccaggc cggagtgcag tggcactatc tcagctcact gc #aagctctg  31380 cctcccgggt tcacgccatt ctcctgcctc agcctcccga gtagctggga ct #acaggtgc  31440 ccgctaccac gcccggctaa ttttttgtat ttttagtaga gatggggttt ca #tggtgtta  31500 gccaggatgg tctcgatctc ctgacctcgt gatccgcccg cctcggcctc cc #aaagtgct  31560 gggattacag gtgtgagcca ccgcgcccag cctagttgga ttcattttta tt #ccacttta  31620 gggattccct ctcattcttg ctgatttcgt gttttggttt tgagcgtttt gt #tattgttg  31680 ctgttgtttt gaatgtttga aacaacgtgg ctgggcacag tgtctcatgc ct #gtaatcct  31740 agcactttgg gaggccaagg cagatggatt gcttgagccc aggagtttga ga #ccagcctg  31800 ggcaacatgg cgaaacctct gtctacaagg aatacaaaaa ttagctgggt gt #ggtagtgc  31860 acacctgaag tcccagctac ctgggaggct gaggtgggag gatcacctga gc #cctgggag  31920 gtcgaggctg cagtgagctg tgatcacacc actgcactcc agcctggcaa ca #gagtgaga  31980 ctctgtctaa aaaaataata ataataaaaa aaataaaaga cattaatgta gc #tccaaaag  32040 tcagaactat acaatacagt aactctccct tttgccctgt tttcttcccc ta #cccccttg  32100 taggtaagca gtctcgttca cttctggttc ctccttcctg ggtttcgttt ag #cacaaaca  32160 ggcagacaca agtatgctat cttcccttct ttctcacagc aagaagtagt ac #cctagact  32220 actctgcttt ccttttgcat ttcttcagtt aacaatttat taggaaaatg at #tccacatt  32280 ggtttgtagg atcttcctca tttttaaaac cactgtatca gggctgggct tg #taatccca  32340 gcactttggg aggctgaggc ggccgaatca cgaggtcagg agttcgagac ca #gcctggcc  32400 aacatggtga aaccccttct ccactaaaaa tacaaaaatt agctgggcgt gg #tggcacac  32460 acctgtaatc ccagcacttt gggaggccaa agcaggcgga tcacttgaga cc #agagttca  32520 aggccaggcc ggccaacatg gtggaacccc atctctacta aaagtacaaa aa #ttagccag  32580 gtatggtggt gggtgcctgt aatcccagct actcgggagg ctgaggcaca ag #aatagctt  32640 gaacccggga ggtggaggtt gtagtgagcc aagatcacgt cactgcactc ca #gcatgggc  32700 gacaaagtga gactccatct caaaaaaatt aataaataaa taatttaaaa at #ttttttaa  32760 aagcctctgt atcagatccc attatgtgga catagcatgg tttattcagc ca #atcttcta  32820 tacatgggca tttaggtttc cagttttaca attacaaaca ctactgcaag gg #ctgatcgt  32880 gcataaacct atttttgtgt tgtgagagga gtgcctgcag ggtgaattta gg #ggtaattg  32940 cacatgtggt tttgttaggc accaccagat ttccctctgt tgggtctgta cc #agtatgtg  33000 tttccaccag cagcttttca gaacctcttt tcccacagcc ttactaacta aa #tgtgccat  33060 tacacgcttg agtttttgcc agtccagtag aggagaatgt attgcagtgg ag #ttttaatt  33120 tacatctctc ctttctgagt gaggtggaac atttttcaga tgcttaaggg cc #atttattt  33180 atttgtttat ttatcggagt ctcactctgt cacccaggct ggagtgcagt gg #cacgatct  33240 cggctcactg caacctccgc ctcccaggtt caagcaattc tcctgcctca gc #ctcccaag  33300 tagctgggat tacaggcgtg agccactgcg cccagccctt cccagtctcg tt #gagacgtg  33360 gcttgtaagg atgtgatgca aggtgtgaac cttccccaga aagaagtgca ta #cgcacagc  33420 acagcctggc tgcagcatct gcttcaaaca aaacagttag ccgagctcca ct #ttctttga  33480 cttaatcatt cttcatgctc cacccatttc cggaaagatg tgaggcatcc ct #ctgatgct  33540 gagcgcaagt ctgtgcacct ctttgccttc ttgtatgttg tgctatgttg cg #tccaattt  33600 gtggcagttg ttttctgttt tcctgctaca gatctaggca gtactgacct gg #gatgggga  33660 agcaggactc tctggcatgg tctttatgct accccaggga aatctgggat ag #ttgaaatc  33720 tgagcagtaa tgtcccttcg ccatgtgtca ggcagaagct gcccactaaa ta #agctctgt  33780 tcagcatgtg tgggcacaga ggggacagtg cagacagact gcagctttat gc #ttacttgg  33840 acacattcct tgacctcttg gaggttctat tttgttgccc agcatagaag ca #gcactcct  33900 gtgttgaagt gatgaagaga acagtgtctg gagccagacc atgtggatga aa #ttcaggtt  33960 ccagcgtgtt ggagccatgt aatgcctggt accgtctgtg tctcagtttc tc #gaacttca  34020 taagtgactt aagatgtgag aactctcaga acagtgccta gcacatagtg ga #cgctcaga  34080 aattgttagc ttttatcatc accaaccaca taatccatat ttgtgggata tt #gtgaggtt  34140 taactcaaat catacaaagt gttcatcata tgtgctccac acattttaat cc #attaaaat  34200 gttcactaac agatttttag gccgggcacg gtggctcacg cctgtaatcc ca #gcactttg  34260 ggaggctgag gcaggcggat cacctgaggt caggagttcg agaccagcct ga #aaccccgt  34320 ctctactaaa aatacaaaaa ttagctgggc gtggtggcat acggaggttg ag #gcaggaga  34380 atcgcttgaa cttgggaggt ggagattaca gtgagcccag atcgtgccgc tg #cactctag  34440 cctgggtgac agagagactc cgtctccaaa aaaagaaata gatttttaga aa #atctttca  34500 cttttcagga agaaagctta tagtctctgt ggctctgtgt tgaggaaaca gc #attaatct  34560 cactacagga gactgcttca ctatcagtta tttctacgtg gaaatatctt ga #ttcccagt  34620 atcattctgt cctgagccca gcacatccca ggctgcccaa atcttgccat gc #tctccttt  34680 gagccaagct gatcttagct tctctcgaaa gtttctgaat tgtcccccat at #ggtctccc  34740 agactcttca gttgaaaaaa ggagccctcc ctgacagccc aggggtcggt gc #ctgctcat  34800 gggaaggtgg ttgctgttga aagcagttat gagcttactg ttcactcaac tc #agtggcca  34860 cctgaccctt tatggtgcat gcaattttac catgtactta tggccaagca ct #acatagtc  34920 aacagacctc attaagttgt caaaaagcat tctcaggctg aggacgttag gc #aacctggc  34980 tttagttggc agaggtgcgt ggacactgcc aaggctccta tttctggttc ca #gtggatga  35040 ggtggaggag gattatttgt aataatagca aacagccagg tgcggtggct ca #cacctgat  35100 aatctcaacg ctttgggagg tggaggtggg aggatcacga gcccaggagt tt #gaggccag  35160 cctagacaac atggtgagac tccatctcta tgaaaaaatt aaaaatcagc tg #ggtgtggt  35220 tgcgcgtgcc tgtagtccca gctactcagg agactgaggc ggaaggaacc ct #tgagccca  35280 ggagttcaag gttacagtga gctatgatcg caccactgta ccccagcctg gg #caacagag  35340 tgagacccta tttctaaaaa gagataataa tagcaaacac acattgagtt ct #aaccaggt  35400 gccaggcagt atactgaggg cttaaatgca gcatcatgtc tgtttctcac ag #caacccta  35460 caaggtaagt gcttgtgatt tctacattgt acagatgagc aagagagatt ca #gtaacatg  35520 ccgaggtctt gtagagggca caaatgcagc cccacagtct cacagcagag cc #cgcagcac  35580 tgcaccacac tgacgcctga gcaaagttca ctccctgact ggagagccac ag #aggcacga  35640 ccgaaggtca ggggacaggg tttcctagca tccgcgagcc ttacagaaag gc #aactgtgc  35700 agtgctccag ctggctttct catggagagt caacagagac atttcccctc ca #gtagaaca  35760 cagaccgtct ctcccctccc ccttgttggt tttacccagg ctttgttttc tg #aaaatgtg  35820 gctgggcctg cttaacatgc ttagcagggc actgggaaat gcacttcagt gg #ccggtgcc  35880 agctagcttt ttggagtttt aaaaagactt tcagaagtct tatttctccc cc #attgaaag  35940 gagggaaaag ggtttttata cagttacttc ttttgagaga aatgtggaaa ca #gtgggacc  36000 agtgaagttc cttccgataa tgaaagagcg atatctgtgt ctgaagcagg ag #gcttgaga  36060 tgatttttat ggacacacca agaaataact gcattcagaa acaggtgaaa tt #cccaacga  36120 tgatgaaaag aaaggactac agatgggaaa attgtgtgtg attacattag ta #tctcttcc  36180 tgaaatgagg gatacattga tagagatgat taaagccaac agtaatcggg ct #agcttgcc  36240 gagtgctaga agtcagtatt tcacagatgg gggtccgttt cttttgcatg tc #aagaaggt  36300 ttacttagca tgttaccagc agaactagtc cagttgtagc tcagtttttc ct #aagcagtg  36360 ggaaaggctg cttatcctgt ctgaaagcag gggttggaga aggagaattt tc #ttagaatt  36420 taacaacaca atctgagact gaaattcttg actggaaatg cggttttgta ca #tgcttggt  36480 gtccctctga tgtcagcatc tcctgagtgt gtataatcta gccccgctgc ct #cctatttt  36540 aaggaattcc ttcagccagg ggtcagctgc tttgttgctg cctggaagca gc #ttatctca  36600 gaatgctctt tctgtttcag gtctctgttc taggatgtcc cgacccagtg gt #gcatgaga  36660 tcgcctatca gtacggaaaa aatgtaggaa tagcttttca ggttagtatg ct #ttttattt  36720 gtaagaatgg tggcgtagtg atacagtcag cattctcccc tagtgtgtaa tc #gtcaaaat  36780 agtaagaacg atggcagcag tgttggcatg gcggtgctcc ttacatccca tt #tttccttt  36840 tgccagctaa tagatgatgt attggacttc acctcgtgtt ctgaccagat gg #gcaaacca  36900 acatcagctg atctgaagct cgggttagcc actggtcctg tcctgtttgc ct #gtcagcag  36960 gtaggtttta caaactccct ttgacacatc actgcatagc cccacagaac tg #atgtcccg  37020 cggcacagct gatgggaaga ttgcataaag gaatagatgg gaaggcattc ag #ataagaga  37080 tcacaggtct gcatttgatc ctggctgagt gagatgttgg ggctggtcat tt #caccttgc  37140 taagactgtt tccttatctg taaaattgag aagatcacct ttctcccagg gt #ggttgtga  37200 ggattagcta agatcctatt tgagatcttt gtgtcttgtg gtgtgccata gg #catttgag  37260 gtagcatcgt gattatttcc atatattttg gccactggca aagtgaacgg tt #tctaagtc  37320 ttgattatag gactggactt tggtggtcct cagagcccct taaaaggcat ag #gaagcatc  37380 aagggcctcc aagcataaga aattctccgg ttctagaagt ttaatgagac tc #tgctgctc  37440 tgagagaggc tttagaacct cggccattgc ctcaaaatgt caggaagtca gt #ggagtgca  37500 gtagacccac atagttcctt ctttctccgg attgagggac tgagtccccc tt #aatgtgaa  37560 tgaaaggctt aggaagcttc aaagatgttc cctcgactga caaagcagac at #tctcacag  37620 cctcctccag accctgccac atggcttgtg gctgtactga atgttacttg aa #ataagtga  37680 gacattagct ggtgttggaa catctcgtta atagattttc atcttagtag ta #tttaattt  37740 gttatgttgc aaagcagtaa gatgttcatc accgtgccat gaaattcaac at #tagctctt  37800 tggtgtaaaa ttatagtaac ttttggtctt tcagagattt tgcctctatt ct #gtcttcac  37860 gtttacaaag gtcagtcatg tcctccataa aattcagtga ttccactgtg at #acagaaac  37920 cacggccctt gcttttggtg ggtttctgat tggagagagg aaaggtcatc tt #tcacccac  37980 tatctagcat agccattggc agcatgattc ttcccagggg aggctgacgt tc #tgggtggc  38040 tggaccaggc tactttggca gcttgctaag gctatgaatg gagatgttgg gg #tactcggt  38100 aggaacaccc gccctcatta ttacaaggct tccatcctct caaactttgg ag #gctgaggt  38160 aagaagtgaa aggtatgctg taaataggtc ctctctccca atgaggctta ct #tgccagcc  38220 caaaatcaaa gagtataata catgtgccca gttttgacaa aaatttataa aa #cctccttt  38280 tgtacattaa ggcaagagtg aggaacattt gagccatgta ggtgttatgc tg #gggattag  38340 aaaaatgagg cactggctac cagtaaccta tataactgcg aacattactt ct #cagatact  38400 tgttagtaaa catgagtgaa ggaaagcaag atggactgag tgtgctgaaa tc #cagctagc  38460 ttggtaaaga ttcctttacc taggctcaga ttatcaggat aaaaggaaaa ag #cctttttc  38520 cctggagaag tctatgagaa agttttggtt gctctatttg taaaaatctt ca #aattgtta  38580 agtacttgtt atgaacccca ggatactaag ttaccggttg agtcctactt aa #accttaag  38640 gtgactgggt gagaggaggc tggcctcttc ggactgtgtt tcactctgaa ta #tatttcag  38700 aagaaactaa cttactttcc cctacacaca caaaggagta atggctatct ct #gctttcat  38760 atatagtggg ggaaagggga aatggacctc tgcatagtat ctgtcagtaa tc #tacaagag  38820 actgaaaaat gctggttagg cggtggctca tgcctgtaat cccagcactt tg #ggaggctg  38880 aggcagttgg attatgaggt caggagttca agaccagcct gaccaatatg gt #ggaaaccc  38940 cgtctctact aaaaatacaa aaattagccg ggcctggtgg tgcatgcctg ta #atcccagc  39000 tactcgggag gccaaggaag gagaatcctt gaacctggga ggcagaggtt gc #agtgagcc  39060 gagactgcac tccagcctgg gtgacagagt gagactccgt ctcaaaaaaa aa #aaaaaagg  39120 ctggttaaaa aaagcaagca aaaggaaaaa aaaagattac tgtacccgaa gc #catggttt  39180 tatgtgtgct ttgctgggaa atcccagtca tgaggcacct actcatgctc ac #cagacagc  39240 agtgttctca tctgcccata aggcagtgag ttgaaaaggc acattgcagc ct #cagaaaag  39300 ggaacacaga atggagtcca agcaggaagt gactctggac aggactcatt tc #aaaagtag  39360 actgatgttt ctgtcttgtg gcacatgggc cagaagttag ccaagtatgt at #ttataagt  39420 tgccttctaa taaaacagca aggttaggct cttttgtgga atacactgta aa #acaagaga  39480 ttcttagcaa gaaatgtgtc aaaagatata tgggactaag attaattcag gt #aaaaacaa  39540 gttccaaaaa taacgtaaga atatgcaata tctccactta atgaaaatgt gt #ttttagtt  39600 tacaaaggat tctttcatac attatctcta atctcacaac tcctctttgt gg #tagatatt  39660 atggtgttta ttctgcaagt aagaaactga tgcccaaacc tcgccaaaat ta #aacatctg  39720 gtaaatggca cagcagggaa ctgaacaagt ctaagaccag tattcatttt at #tacatcat  39780 acatagtgtt attgccactg gtaatgctga gaagttagta gctatgatac ca #cacaggcc  39840 ttcccacaga gcaggtaact aacccacctg ggcactgacg atactcaaag aa #tcatctct  39900 gtgtcatgtc tttgctattg taaacaacat acctacttgg tggagtagtt ct #aagacgtc  39960 tgtaatcctt tccctttggt ag            #                   #              39982 <210> SEQ ID NO 4 <211> LENGTH: 308 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 4 Ala Gln Ala His Arg Gln Lys Gly Leu Asp Le #u Ser Gln Ile Pro Tyr  1               5   #                10   #                15 Phe Asn Leu Val Lys His Leu Thr Pro Ala Cy #s Pro Asn Val Tyr Ser             20       #            25       #            30 Ile Ser Gln Phe His His Thr Thr Pro Tyr Se #r Lys Thr His Ser Gly         35           #        40           #        45 Glu Lys Tyr Thr Asp Pro Phe Lys Leu Gly Tr #p Arg Asp Leu Lys Gly     50               #    55               #    60 Leu Tyr Glu Gly Ile Arg Lys Glu Pro Leu Il #e Ser Thr Thr Glu Leu 65                   #70                   #75                   #80 Lys Glu Ile Ser Glu Tyr Tyr Phe Asp Val Ly #s Gly Lys Ala Phe Arg                 85   #                90   #                95 Pro Ile Ile Val Val Leu Met Ala Arg Ala Cy #s Asn Ile His His Asn             100       #           105       #           110 Asn Ser Arg His Val Gln Ala Ser Gln Arg Al #a Ile Ala Leu Ile Ala         115           #       120           #       125 Glu Met Ile His Thr Ala Ser Leu Val His As #p Asp Val Ile Asp Asp     130               #   135               #   140 Ala Ser Ser Arg Arg Gly Lys His Thr Val As #n Lys Ile Trp Gly Glu 145                 1 #50                 1 #55                 1 #60 Lys Lys Ala Val Leu Ala Gly Asp Leu Ile Le #u Ser Ala Ala Ser Ile                 165   #               170   #               175 Ala Leu Ala Arg Ile Gly Asn Thr Thr Val Il #e Ser Ile Leu Thr Gln             180       #           185       #           190 Val Ile Glu Asp Leu Val Arg Gly Glu Phe Le #u Gln Leu Gly Ser Lys         195           #       200           #       205 Glu Asn Glu Asn Glu Arg Phe Ala His Tyr Le #u Glu Lys Thr Phe Lys     210               #   215               #   220 Lys Thr Ala Ser Leu Ile Ala Asn Ser Cys Ly #s Ala Val Ser Val Leu 225                 2 #30                 2 #35                 2 #40 Gly Cys Pro Asp Pro Val Val His Glu Ile Al #a Tyr Gln Tyr Gly Lys                 245   #               250   #               255 Asn Val Gly Ile Ala Phe Gln Leu Ile Asp As #p Val Leu Asp Phe Thr             260       #           265       #           270 Ser Cys Ser Asp Gln Met Gly Lys Pro Thr Se #r Ala Asp Leu Lys Leu         275           #       280           #       285 Gly Leu Ala Thr Gly Pro Val Leu Phe Ala Cy #s Gln Gln Phe Pro Glu     290               #   295               #   300 Met Asn Ala Met 305 

That which is claimed is:
 1. An isolated polypeptide, wherein the amino acid sequence of said polypeptide consists of SEQ ID NO:2.
 2. An isolated polypeptide, wherein the amino acid sequence of said polypeptide comprises SEQ ID NO:2.
 3. An isolated trans-prenyltransferase, wherein the amino acid sequence of said trans-prenyltransferase consists of an amino sequence having at least 99% sequence identity to SEQ ID NO:2.
 4. An isolated trans-prenyltransferase, wherein the amino acid sequence of said trans-prenyltransferase comprises an amino acid sequence having at least 99% sequence identity to SEQ ID NO:2.
 5. The polypeptide of claim 1, further comprising a heterologous amino acid sequence.
 6. The polypeptide of claim 2, further comprising a heterologous amino acid sequence.
 7. The trans-prenyltransferase of claim 3, further comprising a heterologous amino acid sequence.
 8. The trans-prenyltransferase of claim 4, further comprising a heterologous amino acid sequence.
 9. A composition comprising the polypeptide of claim 1 and a carrier.
 10. A composition comprising the polypeptide of claim 2 and a carrier.
 11. A composition comprising the trans-prenyltransferase of claim 3 and a carrier.
 12. A composition comprising the trans-prenyltransferase of claim 4 and a carrier.
 13. A composition comprising the polypeptide of claim 5 and a carrier.
 14. A composition comprising the polypeptide of claim 6 and a carrier.
 15. A composition comprising the trans-prenyltransferase of claim 7 and a carrier.
 16. A composition comprising the trans-prenyltransferase of claim 8 and a carrier. 